0000855683 2026-01-01 2026-03-31 0000855683 2026-05-11 0000855683 2026-03-31 0000855683 2025-12-31 0000855683 us-gaap:NonrelatedPartyMember 2026-03-31 0000855683 us-gaap:NonrelatedPartyMember 2025-12-31 0000855683 us-gaap:RelatedPartyMember 2026-03-31 0000855683 us-gaap:RelatedPartyMember 2025-12-31 0000855683 2025-01-01 2025-03-31 0000855683 us-gaap:CommonStockMember 2025-12-31 0000855683 us-gaap:AdditionalPaidInCapitalMember 2025-12-31 0000855683 us-gaap:RetainedEarningsMember 2025-12-31 0000855683 us-gaap:TreasuryStockCommonMember 2025-12-31 0000855683 us-gaap:CommonStockMember 2024-12-31 0000855683 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0000855683 us-gaap:RetainedEarningsMember 2024-12-31 0000855683 us-gaap:TreasuryStockCommonMember 2024-12-31 0000855683 2024-12-31 0000855683 us-gaap:CommonStockMember 2026-01-01 2026-03-31 0000855683 us-gaap:AdditionalPaidInCapitalMember 2026-01-01 2026-03-31 0000855683 us-gaap:RetainedEarningsMember 2026-01-01 2026-03-31 0000855683 us-gaap:TreasuryStockCommonMember 2026-01-01 2026-03-31 0000855683 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0000855683 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0000855683 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0000855683 us-gaap:TreasuryStockCommonMember 2025-01-01 2025-03-31 0000855683 us-gaap:CommonStockMember 2026-03-31 0000855683 us-gaap:AdditionalPaidInCapitalMember 2026-03-31 0000855683 us-gaap:RetainedEarningsMember 2026-03-31 0000855683 us-gaap:TreasuryStockCommonMember 2026-03-31 0000855683 us-gaap:CommonStockMember 2025-03-31 0000855683 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0000855683 us-gaap:RetainedEarningsMember 2025-03-31 0000855683 us-gaap:TreasuryStockCommonMember 2025-03-31 0000855683 2025-03-31 0000855683 us-gaap:SubsequentEventMember us-gaap:PrivatePlacementMember 2026-04-20 2026-04-20 0000855683 us-gaap:SubsequentEventMember us-gaap:PrivatePlacementMember 2026-04-20 0000855683 us-gaap:SubsequentEventMember 2026-04-20 0000855683 MLSS:DentalFinishedGoodsMember 2026-03-31 0000855683 MLSS:DentalFinishedGoodsMember 2025-12-31 0000855683 MLSS:MedicalFinishedGoodsMember 2026-03-31 0000855683 MLSS:MedicalFinishedGoodsMember 2025-12-31 0000855683 MLSS:OfficersDirectorsAndOtherEmployeesMember 2026-03-31 0000855683 MLSS:OfficersDirectorsAndOtherEmployeesMember 2025-03-31 0000855683 MLSS:NonemployeesMember 2026-03-31 0000855683 MLSS:NonemployeesMember 2025-03-31 0000855683 us-gaap:EmployeeStockOptionMember 2023-06-28 0000855683 us-gaap:EmployeeStockOptionMember 2023-06-28 2023-06-28 0000855683 us-gaap:EmployeeStockOptionMember 2026-01-01 2026-03-31 0000855683 us-gaap:EmployeeStockOptionMember 2025-01-01 2025-03-31 0000855683 us-gaap:EmployeeStockOptionMember 2026-03-31 0000855683 us-gaap:EmployeeStockOptionMember us-gaap:ShareBasedPaymentArrangementNonemployeeMember 2026-01-01 2026-03-31 0000855683 us-gaap:EmployeeStockOptionMember us-gaap:ShareBasedPaymentArrangementNonemployeeMember 2025-01-01 2025-03-31 0000855683 us-gaap:RestrictedStockMember 2026-01-01 2026-01-01 0000855683 us-gaap:RestrictedStockMember 2026-01-01 2026-03-31 0000855683 us-gaap:RestrictedStockMember 2025-01-01 2025-03-31 0000855683 us-gaap:RestrictedStockMember 2026-03-31 0000855683 us-gaap:EmployeeStockOptionMember us-gaap:ShareBasedPaymentArrangementEmployeeMember 2026-01-01 2026-03-31 0000855683 us-gaap:EmployeeStockOptionMember us-gaap:ShareBasedPaymentArrangementEmployeeMember 2025-12-31 0000855683 us-gaap:EmployeeStockOptionMember us-gaap:ShareBasedPaymentArrangementEmployeeMember 2025-01-01 2025-12-31 0000855683 us-gaap:EmployeeStockOptionMember us-gaap:ShareBasedPaymentArrangementEmployeeMember 2026-03-31 0000855683 us-gaap:EmployeeStockOptionMember us-gaap:ShareBasedPaymentArrangementNonemployeeMember 2025-12-31 0000855683 us-gaap:EmployeeStockOptionMember us-gaap:ShareBasedPaymentArrangementNonemployeeMember 2025-01-01 2025-12-31 0000855683 us-gaap:EmployeeStockOptionMember us-gaap:ShareBasedPaymentArrangementNonemployeeMember 2026-03-31 0000855683 us-gaap:RestrictedStockMember 2025-12-31 0000855683 us-gaap:CorporateNonSegmentMember 2026-01-01 2026-03-31 0000855683 us-gaap:OperatingSegmentsMember MLSS:DentalMember 2026-01-01 2026-03-31 0000855683 us-gaap:OperatingSegmentsMember MLSS:MedicalMember 2026-01-01 2026-03-31 0000855683 MLSS:GrandTotalMember 2026-01-01 2026-03-31 0000855683 us-gaap:CorporateNonSegmentMember 2025-01-01 2025-03-31 0000855683 us-gaap:OperatingSegmentsMember MLSS:DentalMember 2025-01-01 2025-03-31 0000855683 us-gaap:OperatingSegmentsMember MLSS:MedicalMember 2025-01-01 2025-03-31 0000855683 MLSS:GrandTotalMember 2025-01-01 2025-03-31 0000855683 us-gaap:OperatingSegmentsMember MLSS:DentalSegmentMember 2026-03-31 0000855683 us-gaap:OperatingSegmentsMember MLSS:MedicalSegmentMember 2026-03-31 0000855683 us-gaap:CorporateNonSegmentMember 2026-03-31 0000855683 us-gaap:OperatingSegmentsMember MLSS:DentalSegmentMember 2025-12-31 0000855683 us-gaap:OperatingSegmentsMember MLSS:MedicalSegmentMember 2025-12-31 0000855683 us-gaap:CorporateNonSegmentMember 2025-12-31 0000855683 MLSS:ECommerceMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2026-01-01 2026-03-31 0000855683 MLSS:DistributorOneMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2026-01-01 2026-03-31 0000855683 MLSS:ECommerceMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2025-01-01 2025-03-31 0000855683 MLSS:DistributorOneMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2025-01-01 2025-03-31 0000855683 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2026-01-01 2026-03-31 0000855683 MLSS:DistributorOneMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2026-01-01 2026-03-31 0000855683 MLSS:DistributorTwoMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2026-01-01 2026-03-31 0000855683 MLSS:DistributorThreeMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2026-01-01 2026-03-31 0000855683 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2025-01-01 2025-03-31 0000855683 MLSS:DistributorOneMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2025-01-01 2025-12-31 0000855683 MLSS:DistributorTwoMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2025-01-01 2025-12-31 0000855683 MLSS:DistributorThreeMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2025-01-01 2025-12-31 0000855683 us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember 2026-01-01 2026-03-31 0000855683 MLSS:SupplierOneMember us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember us-gaap:RelatedPartyMember 2026-01-01 2026-03-31 0000855683 MLSS:SupplierTwoMember us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember us-gaap:RelatedPartyMember 2026-01-01 2026-03-31 0000855683 MLSS:SupplierThreeMember us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember us-gaap:RelatedPartyMember 2026-01-01 2026-03-31 0000855683 MLSS:SupplierFourMember us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember us-gaap:RelatedPartyMember 2026-01-01 2026-03-31 0000855683 us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember 2025-01-01 2025-12-31 0000855683 MLSS:SupplierOneMember us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember us-gaap:RelatedPartyMember 2025-01-01 2025-12-31 0000855683 MLSS:SupplierTwoMember us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember us-gaap:RelatedPartyMember 2025-01-01 2025-12-31 0000855683 MLSS:SupplierThreeMember us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember us-gaap:RelatedPartyMember 2025-01-01 2025-12-31 0000855683 MLSS:UnitedSystemsMember 2026-01-01 2026-03-31 0000855683 MLSS:UnitedSystemsMember 2025-01-01 2025-03-31 0000855683 MLSS:UnitedSystemsMember 2026-03-31 0000855683 MLSS:UnitedSystemsMember 2025-12-31 0000855683 MLSS:DirectorClinicalAffairMember 2026-01-01 2026-03-31 0000855683 MLSS:DirectorClinicalAffairMember 2025-01-01 2025-03-31 0000855683 MLSS:DirectorClinicalAffairMember 2026-03-31 0000855683 MLSS:DirectorClinicalAffairMember 2025-12-31 0000855683 MLSS:MrOsserViceChairmanOfBoardMember MLSS:EmploymentAgreementMember 2017-07-31 2017-07-31 0000855683 MLSS:MrOsserViceChairmanOfBoardMember MLSS:ConsultingAgreementMember 2017-07-31 2017-07-31 0000855683 MLSS:MrOsserViceChairmanOfBoardMember MLSS:EmploymentAgreementMember 2021-05-19 2021-05-19 0000855683 MLSS:MrOsserViceChairmanOfBoardMember MLSS:ConsultingAgreementMember 2021-05-19 2021-05-19 0000855683 MLSS:MrOsserViceChairmanOfBoardMember MLSS:EmploymentAgreementMember 2026-01-01 2026-03-31 0000855683 MLSS:MrOsserViceChairmanOfBoardMember MLSS:ConsultingAgreementMember 2026-01-01 2026-03-31 0000855683 us-gaap:EmployeeStockOptionMember MLSS:MrOsserViceChairmanOfBoardMember 2021-05-19 2021-05-19 0000855683 MLSS:MrOsserViceChairmanOfBoardMember 2026-03-31 0000855683 MLSS:MrOsserViceChairmanOfBoardMember 2026-01-01 2026-03-31 0000855683 MLSS:UniversityPainMedicineCenterSTEMMEEMember 2026-01-01 2026-03-31 0000855683 MLSS:UniversityPainMedicineCenterSTEMMEEMember 2025-01-01 2025-03-31 0000855683 MLSS:UniversityPainMedicineCenterSTEMMEEMember 2025-01-01 2025-12-31 0000855683 MLSS:JanAdriaanArjanHaverhalsMember 2025-01-01 2025-03-31 0000855683 MLSS:JanAdriaanArjanHaverhalsMember 2025-04-01 2025-06-30 0000855683 MLSS:JanAdriaanArjanHaverhalsMember 2025-07-01 2025-09-30 0000855683 MLSS:JanAdriaanArjanHaverhalsMember 2025-10-01 2025-12-31 0000855683 MLSS:ArjanJHaverhalsAndDirectorMember 2026-01-01 2026-03-31 0000855683 MLSS:ArjanJHaverhalsAndDirectorMember 2025-01-01 2025-12-31 0000855683 MLSS:MrHaverhalsConsultantAndDirectorMember 2026-01-01 2026-03-31 0000855683 MLSS:MrNealGoldmanMsBenedettaCasamentoAndDrDidierDemesminMember 2025-04-09 0000855683 MLSS:MrNealGoldmanMsBenedettaCasamentoAndDrDidierDemesminMember 2025-04-09 2025-04-09 0000855683 MLSS:MrNealGoldmanMember us-gaap:SubsequentEventMember 2026-04-20 0000855683 MLSS:MsBenedettaCasamentoMember us-gaap:SubsequentEventMember 2026-04-20 0000855683 MLSS:DrDidierDemesminMember us-gaap:SubsequentEventMember 2026-04-20 0000855683 MLSS:InnovestSPAMember 2026-01-01 2026-03-31 0000855683 MLSS:InnovestSPAMember 2026-01-15 2026-01-15 0000855683 MLSS:PurchaseCommitmentForDevicesMember 2026-01-01 2026-03-31 0000855683 MLSS:PurchaseCommitmentForDevicesMember 2026-03-31 0000855683 MLSS:PurchaseCommitmentForDevicesMember 2025-12-31 0000855683 MLSS:ContractsForFundingOfFutureEpiduralInstrumentsAndPartsMember 2026-03-31 0000855683 MLSS:ContractsForFundingOfFutureEpiduralInstrumentsAndPartsMember 2025-12-31 0000855683 us-gaap:SubsequentEventMember 2026-04-20 2026-04-20 iso4217:USD shares iso4217:USD shares pure MLSS:Segment MLSS:Integer false --12-31 Q1 0000855683

10-Q true 2026-03-31 2026 false 001-14053 Milestone Scientific Inc. DE 13-3545623 425 Eagle Rock Avenue Suite 403 Roseland NJ 07068 973 535-2717 Common Stock, par value $.001 per share MLSS NYSEAMER Yes Yes Non-accelerated Filer true false false 88075170 0.001

1194424

1112642

10000

555766

680620

22337

25548

22337

25548

676820

468792

3491513

3781837

1411785

1408395

7352645

7477834

18474

19193

61960

79063

51255

55811

121799

150378

332671

24150

7962954

7806429

2269296

1430250

992874

1359698

992874

1359698

1053535

995206

376969

188406

376969

188406

30753

27347

134093

130355

4857520

4131262

20502

27336

35208

800000

5678022

4993806

0.001

125000000

80486449

80453116

80486449

80453116

80487

137731136

137418974

-134615175

-133775322

33333

911516

2284932

2812623

7962954

7806429

2162033

2232420

598009

584985

1564024

1647435

2372653

3256728

369120

19454

19440

2392107

3645288

-828083

-1997853

-11770

3267

-839853

-1994586

-839853

-1994586

-0.01

-0.02

85041913

81854512

80486449

80487

137418974

-133775322

-911516

2812623

256683

55479

-839853

80486449

80487

137731136

-134615175

-911516

2284932

78047798

78048

134719274

-128053106

-911516

5832700

78047798

78048

134719274

-128053106

-911516

5832700

330787

293551 293551

182584

182

-182

-1994586

78230382

78230

135343430

-130047692

-911516

4462452

78230382

78230

135343430

-130047692

-911516

4462452

-839853

-1994586

2351

1985

17103

17455

256683

330787

55479 293551

4014

28579

25875

-120840

43171

-3211

6423

-290324

446281

3390 -331520 332671 208028 185688

839046

896908

-366824

267575

58329

-480382

-188563 -7448 26914 24662

86842

-1008089

1632

1304

-1632

-1304

3428

2278

-3428

-2278

81782

-1011671

1112642

3258058

1194424

2246387

NOTE 1 — ORGANIZATION AND BUSINESS All references in this report to “Milestone Scientific,” “us,” “our,” “we,” the “Company” or “Milestone” refer to Milestone Scientific Inc., and its consolidated subsidiaries, Wand Dental, Inc., and Milestone Innovations Inc. and Milestone Education LLC (all described below), unless the context otherwise indicates. Milestone Scientific is the owner of the following registered U.S. trademarks: CompuDent®; CompuMed®; CompuFlo®; DPS Dynamic Pressure Sensing technology®; Milestone Scientific ®; the Milestone logo ®; SafetyWand®; STA Single Tooth Anesthesia System®; and The Wand ®. Milestone Scientific was incorporated in the State of Delaware in August 1989. Milestone Scientific has developed a proprietary, computer-controlled delivery device, using The Wand®, a single-use disposable handpiece. The device is marketed in dentistry under the trademark CompuDent®, STA Single Tooth Anesthesia System®, and in medicine under the trademark CompuMed®. CompuDent® is suitable for all dental procedures that require a local anesthetic. CompuMed® is suitable for many medical procedures regularly performed in plastic surgery, hair restoration surgery, podiatry, colorectal surgery, dermatology, orthopedics, and many other disciplines. The dental devices are sold in the United States, Canada and in 33 other countries. Certain medical devices have obtained CE mark approval and can be marketed and sold in most European countries. In June 2017, Milestone Scientific received 510(k) marketing clearance from the U.S. Food and Drug Administration (FDA) on the CompuFlo® Epidural Computer Controlled Anesthesia System (“Epidural”).

NOTE 2 — GOING CONCERN AND LIQUIDITY Our financial statements have been prepared in conformity with generally accepted accounting principles, which contemplate continuation of the Company on a going concern basis. The going concern basis assumes that assets are realized, and liabilities are extinguished in the ordinary course of business at amounts disclosed in the financial statements. The Company has incurred total losses since its inception of $134.6 million. The Company’s operating losses were approximately $828,000 and $2.0 million for the three months ended March 31, 2026, and 2025, respectively. On March 31, 2026, Milestone Scientific had cash and cash equivalents of approximately $1.2 million and working capital of approximately $2.5 million. For the three months ended March 31, 2026 and 2025, we had cash flows provided by (used in) operating activities of approximately $0.1 million and $(1.0) million, respectively. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. On April 20, 2026, the Company completed a private placement of <span id="xdx_906_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20260420__20260420__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z6YVbtVZpTG4" title="Sale of stock number of shares issued in transaction">7,962,963 units at a purchase price of $<span id="xdx_90E_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20260420__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z3EtPRU42V4k" title="Sale of stock price per share">0.27 per unit, generating gross proceeds of approximately $<span id="xdx_900_eus-gaap--SaleOfStockConsiderationReceivedPerTransaction_pn4n6_c20260420__20260420__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zhGKbdiG64j8" title="Sale of stock consideration received per transaction">2.15 million, consisting of $1.80 million in cash and a reduction of $351,000 in outstanding principal of the Company’s outstanding convertible notes, the holders of which applied such principal amounts toward the purchase of units in the offering in lieu of cash (the “Private Placement”). Each unit consisted of one share of common stock and one warrant to purchase one share of common stock at an exercise price of $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260420__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zOH9WKD6Xwv3" title="Warrant exercise price">0.3375 per share, exercisable for a period of three years. If fully exercised, the warrants would provide up to approximately $<span id="xdx_90F_eus-gaap--ProceedsFromWarrantExercises_pn4n6_c20260420__20260420__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zOWXy6QWR4wf" title="Proceeds from warrant exercise">2.69 million in additional gross proceeds. The Company intends to use the net proceeds from the private placement for general working capital purposes and the payment of outstanding accounts payable and accrued liabilities. The Company’s recurring losses from operations, negative cash flows, and accumulated deficit raise substantial doubt about its ability to continue as a going concern. The completion of the private placement in April 2026 has improved the Company’s liquidity position; however, the Company’s ability to continue as a going concern is dependent upon its ability to generate sufficient revenue, manage operating expenses, and, if necessary, obtain additional financing

-134600000

828000 2000000.0

1200000

2500000

100000

-1000000.0

7962963

0.27

2150000

1800000

351000

0.3375

2690000

NOTE 3 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES 1. Principles of Consolidation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”), and the applicable rules and regulations of the Securities and Exchange Commission (SEC) include the accounts of Milestone Scientific and its wholly owned subsidiaries, including Wand Dental and Milestone Innovations Inc. All significant intra-entity transactions and balances have been eliminated in the consolidation. 2. Basis of Presentation The unaudited condensed consolidated financial statements of Milestone Scientific have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) for interim financial information with the instructions for Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all the information and footnotes required by GAAP for complete annual financial statements. In the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments (consisting of normal recurring entries) necessary to present such interim results fairly. Interim results are not necessarily indicative of the results of operations that may be expected for a full year or any subsequent period. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2025, included in Milestone Scientific’s Annual Report on Form 10-K. 3. Use of Estimates The preparation of unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions in determining the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. The most significant estimates relate to the inventory valuation and cash flow assumptions regarding evaluations of going concern considerations. The Company bases its estimates on historical experience, known trends, and other market-specific or relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates as there are changes in circumstances, facts, and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates. 4. Revenue Recognition The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To achieve revenue recognition, the Company performs the following five steps: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">i.</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">identification of the promised goods or services in the contract;</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif">ii.</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif">iii.</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">measurement of the transaction price, including the constraint on variable consideration;</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif">iv.</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">allocation of the transaction price to the performance obligations based on estimated selling prices; and</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif">v.</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">recognition of revenue when (or as) the Company satisfies each performance obligation. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in ASC 606.</td></tr> </table> The Company derives its revenues from the sale of its products, primarily dental and medical instruments, handpieces, and other related products. The Company sells its products directly to consumers in the United States and through a global distribution network that includes both exclusive and non-exclusive international distribution agreements. Revenue is recognized at the point of shipment for all sales. The Company has no obligation to product sales for any installation, set-up, or maintenance, these being the responsibility of the buyer. Milestone Scientific’s only obligation after sale is the normal commercial warranty against manufacturing defects if the alleged defective unit is returned within the warranty period. E-Commerce The Company sells its STA Single Tooth Anesthesia Systems® (STA) and handpieces directly to dental offices and dental groups within the United States via an online portal. The Company’s E-Commerce portal accepts online payments via credit and debit cards. The cost of delivery is charged to the customer along with appropriate sales tax. The Company recognizes revenue from product sales at the time the product ships to a customer via a third-party carrier. Sales Returns The Company records allowances for product returns as a reduction of revenue at the time product sales are recorded. Several factors are considered in determining whether an allowance for product returns is required, including the customers’ return rights, the Company’s historical experience with returns, and the amount of product in the distribution channel not consumed by end users and subject to return. The Company relies on historical return rates to estimate returns. Financing and Payment The Company’s payment terms differ by geography and customer, but payments from distributors are required within 90 days or less from the date of shipment. The E-Commerce portal sells directly to end users and accepts online payments via credit and debit cards through a third-party. These payments from the third party are typically settled within two business days. Segments The Company operates in two operating segments: Dental and Medical. The Company evaluates each of the two segments based on performance, using financial information compiled utilizing the accounting policies listed in Note 3 of this Form 10-Q. The profitability of the segment helps the Company evaluate staffing levels, assess available cash for allocation to projects and resources, and make informed decisions on whether the segment’s activities should be modified to align with the Company’s overall near- and long-term strategies. See Note 9 for segments by geographical market, based on the customer’s location, and product category for the three months ended March 31, 2026 and 2025, respectively. 5. Cash and Cash Equivalents Milestone Scientific considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. As of March 31, 2026 and December 31, 2025, Milestone Scientific has approximately $1.2 million and $1.1 million, respectively of cash. As of March 31, 2026, Milestone Scientific had cash in accounts that exceeded the Federal Deposit Insurance Corporation insurance limit of $250,000. 6. Accounts Receivable The E-commerce portal sells directly to end users and accepts online payments via credit and debit cards via a third-party credit card processor. These payments are settled within 2 business days of the transactions. Sales to distributors are on credit terms. The Company estimates losses from the ability or inability of its distributor to make payments on bills. Distributors’ credit sales are due 90 days or less from the date of invoicing. As of March 31, 2026, and December 31, 2025, accounts receivable was recorded, net of allowance for credit losses of $10,000, respectively. 7. Inventories Inventories principally consist of finished goods and component parts stated at the lower cost (first-in, first-out method) or net realizable value. Inventory quantities on hand are reviewed on a quarterly basis, and a provision for excess slow-moving, defective, and obsolete inventory is recorded if required based on past and expected future sales, potential technological obsolescence, and product expiration requirements. The valuation allowance creates a new cost basis for the inventory, and it is not subsequently marked up through a reduction in the valuation allowance based on any changes in the underlying facts and circumstances. When the valuation allowance is initially recorded, the increase to the allowance is recognized as an increase in cost of sales. The valuation allowance is only reduced if or when the underlying inventory is sold or destroyed, at which time cost of sales recognized would include the previous adjusted cost basis. 8. Basic and Diluted Net Loss Per Common Share Milestone Scientific presents “basic” earnings (loss) per common share applicable to common stockholders and, if applicable, “diluted” earnings (loss) per common share applicable to common stockholders pursuant to the provisions of ASC 260, “Earnings per Share”. Basic earnings (loss) per common share is calculated by dividing net income or loss applicable to common stockholders by the weighted average number of common shares outstanding and to be issued common shares as follows: 85,041,913 and 81,854,512 for the three months ended March 31, 2026 and 2025, respectively. The calculation of diluted earnings per common share is like that of basic earnings per common share, except that the denominator is increased to include the number of additional common shares that would have been outstanding if all potentially dilutive common shares, such as those issuable upon the exercise of stock options and warrants, were issued during the period. Since Milestone Scientific had net losses in the three months ended March 31, 2026, and 2025, the assumed effects of the exercise of potentially dilutive outstanding stock options, unissued restricted stock awards (“RSA”) and warrants were not included in the calculation as their effect would have been anti-dilutive. Such outstanding options, RSA’s and warrants totaled 8,178,028 and 3,242,906 for the three months ended March 31, 2026 and 2025, respectively. 9. Recent Accounting Pronouncements Recently Issued Accounting Pronouncement In November 2024, the Financial Accounting Standards Board, “FASB”, issued Accounting Standards Update “ASU” 2024-03, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40), to improve the disaggregation of expenses within the consolidated statement of operations. The amendments in ASU 2024-03 require disclosures, in the notes to the consolidated financial statements, specified information about certain costs and expenses. The amendments require that at each interim and annual reporting period an entity disclose (a) employee compensation, (b) depreciation, and (c) intangible asset amortization included in each relevant expense caption; include certain amounts that are already required to be disclosed under current generally accepted accounting principles (GAAP) in the same disclosure as the other disaggregation requirements; and disclose a qualitative description of the amounts remaining in relevant expense captions that are not separately disaggregated quantitatively. The amendments in ASU 2024-03 are effective January 1, 2027, and effective for interim periods beginning January 1, 2028. Early adoption is permitted for annual financial statements that have not yet been issued or made available for issuance. The Company will evaluate the impact of ASU 2024-03 on its financial statements.

1. Principles of Consolidation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”), and the applicable rules and regulations of the Securities and Exchange Commission (SEC) include the accounts of Milestone Scientific and its wholly owned subsidiaries, including Wand Dental and Milestone Innovations Inc. All significant intra-entity transactions and balances have been eliminated in the consolidation.

2. Basis of Presentation The unaudited condensed consolidated financial statements of Milestone Scientific have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) for interim financial information with the instructions for Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all the information and footnotes required by GAAP for complete annual financial statements. In the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments (consisting of normal recurring entries) necessary to present such interim results fairly. Interim results are not necessarily indicative of the results of operations that may be expected for a full year or any subsequent period. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2025, included in Milestone Scientific’s Annual Report on Form 10-K.

3. Use of Estimates The preparation of unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions in determining the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. The most significant estimates relate to the inventory valuation and cash flow assumptions regarding evaluations of going concern considerations. The Company bases its estimates on historical experience, known trends, and other market-specific or relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates as there are changes in circumstances, facts, and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates.

4. Revenue Recognition The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To achieve revenue recognition, the Company performs the following five steps: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">i.</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">identification of the promised goods or services in the contract;</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif">ii.</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif">iii.</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">measurement of the transaction price, including the constraint on variable consideration;</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif">iv.</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">allocation of the transaction price to the performance obligations based on estimated selling prices; and</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif">v.</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">recognition of revenue when (or as) the Company satisfies each performance obligation. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in ASC 606.</td></tr> </table> The Company derives its revenues from the sale of its products, primarily dental and medical instruments, handpieces, and other related products. The Company sells its products directly to consumers in the United States and through a global distribution network that includes both exclusive and non-exclusive international distribution agreements. Revenue is recognized at the point of shipment for all sales. The Company has no obligation to product sales for any installation, set-up, or maintenance, these being the responsibility of the buyer. Milestone Scientific’s only obligation after sale is the normal commercial warranty against manufacturing defects if the alleged defective unit is returned within the warranty period. E-Commerce The Company sells its STA Single Tooth Anesthesia Systems® (STA) and handpieces directly to dental offices and dental groups within the United States via an online portal. The Company’s E-Commerce portal accepts online payments via credit and debit cards. The cost of delivery is charged to the customer along with appropriate sales tax. The Company recognizes revenue from product sales at the time the product ships to a customer via a third-party carrier. Sales Returns The Company records allowances for product returns as a reduction of revenue at the time product sales are recorded. Several factors are considered in determining whether an allowance for product returns is required, including the customers’ return rights, the Company’s historical experience with returns, and the amount of product in the distribution channel not consumed by end users and subject to return. The Company relies on historical return rates to estimate returns. Financing and Payment The Company’s payment terms differ by geography and customer, but payments from distributors are required within 90 days or less from the date of shipment. The E-Commerce portal sells directly to end users and accepts online payments via credit and debit cards through a third-party. These payments from the third party are typically settled within two business days. Segments The Company operates in two operating segments: Dental and Medical. The Company evaluates each of the two segments based on performance, using financial information compiled utilizing the accounting policies listed in Note 3 of this Form 10-Q. The profitability of the segment helps the Company evaluate staffing levels, assess available cash for allocation to projects and resources, and make informed decisions on whether the segment’s activities should be modified to align with the Company’s overall near- and long-term strategies. See Note 9 for segments by geographical market, based on the customer’s location, and product category for the three months ended March 31, 2026 and 2025, respectively.

5. Cash and Cash Equivalents Milestone Scientific considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. As of March 31, 2026 and December 31, 2025, Milestone Scientific has approximately $1.2 million and $1.1 million, respectively of cash. As of March 31, 2026, Milestone Scientific had cash in accounts that exceeded the Federal Deposit Insurance Corporation insurance limit of $250,000.

1200000

1100000

250000

6. Accounts Receivable The E-commerce portal sells directly to end users and accepts online payments via credit and debit cards via a third-party credit card processor. These payments are settled within 2 business days of the transactions. Sales to distributors are on credit terms. The Company estimates losses from the ability or inability of its distributor to make payments on bills. Distributors’ credit sales are due 90 days or less from the date of invoicing. As of March 31, 2026, and December 31, 2025, accounts receivable was recorded, net of allowance for credit losses of $10,000, respectively.

10000

7. Inventories Inventories principally consist of finished goods and component parts stated at the lower cost (first-in, first-out method) or net realizable value. Inventory quantities on hand are reviewed on a quarterly basis, and a provision for excess slow-moving, defective, and obsolete inventory is recorded if required based on past and expected future sales, potential technological obsolescence, and product expiration requirements. The valuation allowance creates a new cost basis for the inventory, and it is not subsequently marked up through a reduction in the valuation allowance based on any changes in the underlying facts and circumstances. When the valuation allowance is initially recorded, the increase to the allowance is recognized as an increase in cost of sales. The valuation allowance is only reduced if or when the underlying inventory is sold or destroyed, at which time cost of sales recognized would include the previous adjusted cost basis.

8. Basic and Diluted Net Loss Per Common Share Milestone Scientific presents “basic” earnings (loss) per common share applicable to common stockholders and, if applicable, “diluted” earnings (loss) per common share applicable to common stockholders pursuant to the provisions of ASC 260, “Earnings per Share”. Basic earnings (loss) per common share is calculated by dividing net income or loss applicable to common stockholders by the weighted average number of common shares outstanding and to be issued common shares as follows: 85,041,913 and 81,854,512 for the three months ended March 31, 2026 and 2025, respectively. The calculation of diluted earnings per common share is like that of basic earnings per common share, except that the denominator is increased to include the number of additional common shares that would have been outstanding if all potentially dilutive common shares, such as those issuable upon the exercise of stock options and warrants, were issued during the period. Since Milestone Scientific had net losses in the three months ended March 31, 2026, and 2025, the assumed effects of the exercise of potentially dilutive outstanding stock options, unissued restricted stock awards (“RSA”) and warrants were not included in the calculation as their effect would have been anti-dilutive. Such outstanding options, RSA’s and warrants totaled 8,178,028 and 3,242,906 for the three months ended March 31, 2026 and 2025, respectively.

85041913

81854512

8178028

3242906

9. Recent Accounting Pronouncements Recently Issued Accounting Pronouncement In November 2024, the Financial Accounting Standards Board, “FASB”, issued Accounting Standards Update “ASU” 2024-03, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40), to improve the disaggregation of expenses within the consolidated statement of operations. The amendments in ASU 2024-03 require disclosures, in the notes to the consolidated financial statements, specified information about certain costs and expenses. The amendments require that at each interim and annual reporting period an entity disclose (a) employee compensation, (b) depreciation, and (c) intangible asset amortization included in each relevant expense caption; include certain amounts that are already required to be disclosed under current generally accepted accounting principles (GAAP) in the same disclosure as the other disaggregation requirements; and disclose a qualitative description of the amounts remaining in relevant expense captions that are not separately disaggregated quantitatively. The amendments in ASU 2024-03 are effective January 1, 2027, and effective for interim periods beginning January 1, 2028. Early adoption is permitted for annual financial statements that have not yet been issued or made available for issuance. The Company will evaluate the impact of ASU 2024-03 on its financial statements.

NOTE 4 — INVENTORIES Inventories consist of the following: SCHEDULE OF INVENTORIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49B_20260331_z0euTTUYG038" style="border-bottom: Black 1pt solid; text-align: center">March 31, 2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_499_20251231_zsu3pxQq5Tki" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_407_eus-gaap--InventoryFinishedGoodsNetOfReserves_iI_hus-gaap--PublicUtilitiesInventoryAxis__custom--DentalFinishedGoodsMember_zTbEoASW7f09" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Dental finished goods</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">3,276,004</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">3,598,270</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--InventoryFinishedGoodsNetOfReserves_iI_hus-gaap--PublicUtilitiesInventoryAxis__custom--MedicalFinishedGoodsMember_zVs4CGl0tGDg" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Medical finished goods</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">114,490</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">108,975</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--InventoryFinishedGoodsNetOfReserves_iI_hus-gaap--PublicUtilitiesInventoryAxis__custom--MedicalFinishedGoodsMember_zDpd5BR6Tfif" style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: left">Inventory finished goods</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">114,490</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">108,975</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--InventoryPartsAndComponentsNetOfReserves_iI_zuhgcnqRGN23" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Component parts and other materials</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">101,019</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">74,592</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--InventoryNet_iI_zkg8ykdIW7x5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total inventories</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,491,513</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,781,837</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> The Company had an allowance on slow moving Medical finished goods due to the slow adoption of the epidural instruments and handpieces for approximately $1.0 million and $1.1 million as of March 31, 2026, and December 31, 2025, respectively.

Inventories consist of the following: SCHEDULE OF INVENTORIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49B_20260331_z0euTTUYG038" style="border-bottom: Black 1pt solid; text-align: center">March 31, 2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_499_20251231_zsu3pxQq5Tki" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_407_eus-gaap--InventoryFinishedGoodsNetOfReserves_iI_hus-gaap--PublicUtilitiesInventoryAxis__custom--DentalFinishedGoodsMember_zTbEoASW7f09" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Dental finished goods</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">3,276,004</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">3,598,270</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--InventoryFinishedGoodsNetOfReserves_iI_hus-gaap--PublicUtilitiesInventoryAxis__custom--MedicalFinishedGoodsMember_zVs4CGl0tGDg" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Medical finished goods</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">114,490</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">108,975</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--InventoryFinishedGoodsNetOfReserves_iI_hus-gaap--PublicUtilitiesInventoryAxis__custom--MedicalFinishedGoodsMember_zDpd5BR6Tfif" style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: left">Inventory finished goods</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">114,490</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">108,975</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--InventoryPartsAndComponentsNetOfReserves_iI_zuhgcnqRGN23" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Component parts and other materials</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">101,019</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">74,592</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--InventoryNet_iI_zkg8ykdIW7x5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total inventories</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,491,513</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,781,837</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

3276004

3598270

114490

108975

114490

108975

101019

74592

3491513

3781837

1000000.0

1100000

NOTE 5 — ADVANCES ON CONTRACTS The advances on contracts represent funding for future STA devices, epidural instruments, and epidural replacement parts. The balance of the advances as of March 31, 2026 and December 31, 2025, is approximately $1.4 million, respectively. The advance is classified as current based on the estimated annual usage of the underlying inventory.

1400000

NOTE 6— STOCKHOLDERS’ EQUITY SHARES TO BE ISSUED As of March 31, 2026, and 2025, there were <span id="xdx_90F_eus-gaap--DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance_iI_c20260331__srt--TitleOfIndividualAxis__custom--OfficersDirectorsAndOtherEmployeesMember_zOwKiFvocxUe" title="Shares to be issued">3,617,696 and <span id="xdx_90D_eus-gaap--DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance_iI_c20250331__srt--TitleOfIndividualAxis__custom--OfficersDirectorsAndOtherEmployeesMember_zmKnpaY0kqyd" title="Shares to be issued">3,076,871 shares to be issued, respectively, whose issuance has been deferred under the terms of employment and consulting agreements with officers and directors and other employees of Milestone Scientific. Such shares will be issued to each party upon termination of their employment or other relationship with the Company. As of March 31, 2026 and 2025 there were <span id="xdx_90D_eus-gaap--DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance_iI_c20260331__srt--TitleOfIndividualAxis__custom--NonemployeesMember_z0m3wGkbJwVh" title="Shares to be issued">1,002,162 and <span id="xdx_90A_eus-gaap--DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance_iI_c20250331__srt--TitleOfIndividualAxis__custom--NonemployeesMember_zuLU1sJSuw17" title="Shares to be issued">631,792 respectively, shares to be issued to non-employees, that will be issued to non-employees for services rendered. The number of shares was fixed by contract prior to the date of grant, subject to performance, and were fully earned upon the grant date. <p id="xdx_89F_ecustom--DeferredCompensationArrangementWithIndividualSharebasedPaymentsTableTextBlock_zDakqGPg74Z9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The following table summarizes information about shares to be issued for the three month periods ending March 31, 2026 and 2025. SCHEDULE OF SHARES TO BE ISSUED <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49F_20260101__20260331_zT1oDZqJM6Og" style="border-bottom: Black 1pt solid; text-align: center">March 31, 2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_493_20250101__20250331_z8fKsMzMjLB5" style="border-bottom: Black 1pt solid; text-align: center">March 31, 2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_404_eus-gaap--DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance_iS_zNboP8PJfBKa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Shares-to-be-issued, outstanding January 1, 2026 and 2025, respectively</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">4,449,403</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">3,393,017</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance_iS_zLIxRZXAkqCi" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Shares-to-be-issued, outstanding beginning balance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,449,403</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,393,017</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_ecustom--DeferredCompensationArrangementWithIndividualSharesGranted_z2q8rJVlUY09" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Granted in current period</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">170,455</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">315,646</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--DeferredCompensationArrangementWithIndividualSharesIssued_iN_di_zxTVHBKlc5sk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Issued in current period</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"></td></tr> <tr id="xdx_40A_eus-gaap--DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance_iE_zZlRDI0tjrub" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Shares-to be issued outstanding March 31, 2026 and 2025, respectively</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">4,619,858</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">3,708,663</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance_iE_zLJWbDbNMgm" style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Shares-to be issued outstanding ending balance</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">4,619,858</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">3,708,663</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

3617696

3076871

1002162

631792

<p id="xdx_89F_ecustom--DeferredCompensationArrangementWithIndividualSharebasedPaymentsTableTextBlock_zDakqGPg74Z9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The following table summarizes information about shares to be issued for the three month periods ending March 31, 2026 and 2025. SCHEDULE OF SHARES TO BE ISSUED <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49F_20260101__20260331_zT1oDZqJM6Og" style="border-bottom: Black 1pt solid; text-align: center">March 31, 2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_493_20250101__20250331_z8fKsMzMjLB5" style="border-bottom: Black 1pt solid; text-align: center">March 31, 2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_404_eus-gaap--DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance_iS_zNboP8PJfBKa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Shares-to-be-issued, outstanding January 1, 2026 and 2025, respectively</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">4,449,403</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">3,393,017</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance_iS_zLIxRZXAkqCi" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Shares-to-be-issued, outstanding beginning balance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,449,403</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,393,017</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_ecustom--DeferredCompensationArrangementWithIndividualSharesGranted_z2q8rJVlUY09" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Granted in current period</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">170,455</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">315,646</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--DeferredCompensationArrangementWithIndividualSharesIssued_iN_di_zxTVHBKlc5sk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Issued in current period</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"></td></tr> <tr id="xdx_40A_eus-gaap--DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance_iE_zZlRDI0tjrub" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Shares-to be issued outstanding March 31, 2026 and 2025, respectively</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">4,619,858</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">3,708,663</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance_iE_zLJWbDbNMgm" style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Shares-to be issued outstanding ending balance</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">4,619,858</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">3,708,663</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

4449403

3393017

4449403

3393017

170455 315646

4619858

3708663

4619858

3708663

NOTE 7 — STOCK OPTION PLANS The Milestone Scientific Inc., Amended and Restated 2020 Equity Incentive Plan, provides for awards of restricted common, stock restricted stock units, options to purchase and other awards. On June 28, 2023 the plan was amended and restated (the “2020 Plan”) to increase the maximum shares that can be issued thereunder to 11,500,000 shares of common stock. The plan expires in June 2031. Options may be granted to employees, directors, and consultants of Milestone Scientific for the purchase of shares of common stock at a price not less than the fair market value of common stock on the date of grant. Generally, options become exercisable over a 3-year period from the grant date and expire 5 years after the date of grant. Milestone Scientific recognizes compensation expenses over the requisite service period and in the case of performance-based options over the period of the expected performance. For the three months ended March 31, 2026, and 2025, Milestone Scientific recognized approximately $257,000 and $171,000 of total employee compensation cost, respectively, recorded in general and administrative expenses on the statement of operations. As of March 31, 2026, there was $<span id="xdx_90B_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pn5n6_c20260331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z6XLhwBLiAN4" title="Unrecognized compensation expense">1.0 million of total unrecognized compensation cost related to non-vested options. Milestone Scientific expects to recognize these costs over a weighted average period of <span id="xdx_900_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zLnmPCQPhv48" title="Weighted average period">1.9 years. <p id="xdx_894_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_hus-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zgToQ3DVuAjk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">A summary of option activity for employees under the plans and changes during the three months ended March 31, 2026 is presented below: SCHEDULE OF STOCK OPTION ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number of Options</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted Averaged Exercise Price $</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Remaining Contractual Life (Years)</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Aggregate Intrinsic Options Value $</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Options outstanding at January 1, 2026</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zn1MKcAwAjqi" style="width: 11%; text-align: right" title="Number of Options Outstanding, Beginning Balance">6,032,175</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zsghd9gCgAb8" style="width: 11%; text-align: right" title="Weighted Averaged Exercise Price, Beginning Balance">1.15</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zxFeO8JyUKrb" title="Weighted Average Remaining Contractual Life (Years), Outstanding">8.13</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zW8WAKCI5S3k" style="width: 11%; text-align: right" title="Aggregate Intrinsic Options Value, Beginning Balance">-</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Granted during 2026</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z83dhwpfn3S6" style="text-align: right" title="Number of Options, Granted">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zWkukp0cZMX7" style="text-align: right" title="Weighted Averaged Exercise Price, Granted">-</td><td style="text-align: left"> </td><td style="font-style: normal"> </td> <td style="font-style: normal; text-align: left"> </td><td style="font-style: normal; text-align: right"> </td><td style="font-style: normal; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Exercised during 2026</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zdNyvXbsBQQd" style="text-align: right" title="Number of Options, Exercised">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zC34v1r36Sc" style="text-align: right" title="Weighted Averaged Exercise Price, Exercised">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Forfeited or expired during 2026</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zy7Ywsn5Fkj7" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options, Forfeited or expired">(32,175</td><td style="text-align: left">) </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zbLcd91EPtNe" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Averaged Exercise Price, Forfeited or expired">3.11</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Options outstanding March 31, 2026</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_ztCLEtWW53n3" style="text-align: right" title="Number of Options Outstanding, Ending Balance">6,000,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zj0Exvkynr5g" style="text-align: right" title="Weighted Averaged Exercise Price, Ending Balance">1.14</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zkgBlZsW6Imh" title="Weighted Average Remaining Contractual Life (Years), Outstanding">7.92</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zmVCFPLBWX7b" style="text-align: right" title="Aggregate Intrinsic Options Value, Ending Balance">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Exercisable, March 31, 2026</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zweHRLmeJP13" style="text-align: right" title="Number of Options, Exercisable">2,000,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zxuimYEGOkV9" style="text-align: right" title="Weighted Averaged Exercise Price, Exercisable">2.06</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zcUOekKFRRJe" title="Weighted Average Remaining Contractual Life (Years), Exercisable">5.92</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zKiRvlpR8CN6" style="text-align: right" title="Aggregate Intrinsic Options Value, Exercisable">-</td><td style="text-align: left"> </td></tr> </table> <p id="xdx_891_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_hus-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zeYhNN7qdC36" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">A summary of option activity for non-employees under the plans and changes during the three months ended March 31, 2026 is presented below: SCHEDULE OF STOCK OPTION ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Number of Options</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"> </td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Weighted Averaged Exercise Price $</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"> </td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Weighted Average Remaining Contractual Life (Years)</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"> </td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Aggregate Intrinsic Options Value $</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; font-size: 10pt">Options outstanding at January 1, 2026</td><td style="width: 2%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zrsh4AgrWxP4" style="width: 11%; font-size: 10pt; text-align: right" title="Number of Options Outstanding, Beginning Balance">83,330</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 2%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zAYJ2vba0Qs4" style="width: 11%; font-size: 10pt; text-align: right" title="Weighted Averaged Exercise Price, Beginning Balance">1.59</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 2%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 11%; font-size: 10pt; text-align: right"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_ztbA6DJQgnvf" title="Weighted Average Remaining Contractual Life (Years), Outstanding">2.40</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 2%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zU03yCg5AOad" style="width: 11%; font-size: 10pt; text-align: right" title="Aggregate Intrinsic Options Value, Beginning Balance">-</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Granted during 2026</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zpfemakx2gs2" style="font-size: 10pt; text-align: right" title="Number of Options, Granted">-</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zA5AsBNyaVB3" style="font-size: 10pt; text-align: right" title="Weighted Averaged Exercise Price, Granted">-</td><td style="font-size: 10pt; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Exercised during 2026</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zt9A3XMr67k3" style="font-size: 10pt; text-align: right" title="Number of Options, Exercised">-</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zWNWtwEPUAug" style="font-size: 10pt; text-align: right" title="Weighted Averaged Exercise Price, Exercised">-</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Forfeited or expired during 2026</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zXttPLWafpo4" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Number of Options, Forfeited or expired">(16,666</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zCMSnpcNvDif" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Weighted Averaged Exercise Price, Forfeited or expired">3.94</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt">Options outstanding March 31, 2026</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zWWrBB4iWU79" style="font-size: 10pt; text-align: right" title="Number of Options Outstanding, Ending Balance">66,664</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z1aex6GRg0w" style="font-size: 10pt; text-align: right" title="Weighted Averaged Exercise Price, Ending Balance">1.00</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zGoZvj4mSTS8" title="Weighted Average Remaining Contractual Life (Years), Outstanding">2.70</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zWznmyYD1h7k" style="font-size: 10pt; text-align: right" title="Aggregate Intrinsic Options Value, Ending Balance">-</td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt">Exercisable, March 31, 2026</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zgKxVEVSzcYk" style="font-size: 10pt; text-align: right" title="Number of Options, Exercisable">49,994</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zihfrgQgl9h1" style="font-size: 10pt; text-align: right" title="Weighted Averaged Exercise Price, Exercisable">1.02</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_znvpWHuZrWve" title="Weighted Average Remaining Contractual Life (Years), Exercisable">2.35</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_znk2w9xOqVi8" style="font-size: 10pt; text-align: right" title="Aggregate Intrinsic Options Value, Exercisable">-</td><td style="font-size: 10pt; text-align: left"> </td></tr> </table> For the three months ended March 31, 2026, and 2025 Milestone Scientific recognized approximately $<span id="xdx_90F_eus-gaap--AllocatedShareBasedCompensationExpense_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zQd3BU00ch0f" title="Stock compensation expense">1,200 and $<span id="xdx_902_eus-gaap--AllocatedShareBasedCompensationExpense_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zdu93uDKICh5" title="Stock compensation expense">6,600 expense related to non-employee options, respectively. <p id="xdx_898_eus-gaap--DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_hus-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zghbHynJStN3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">A summary of restricted stock under the plans and changes during the three months ended March 31, 2026 is presented below: SCHEDULE OF RESTRICTED STOCK <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of Shares</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Grant-Date Fair Value per Award</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Non-vested as January 1, 2026</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_ziGZuPOWOvWk" style="width: 16%; text-align: right" title="Number of Shares, Non-vested Beginning Balance">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zmICkbdRPfAc" style="width: 16%; text-align: right" title="Weighted Average Grant-Date Fair Value per Award, Non-vested Beginning Balance">-</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zBHW16InGEm2" style="text-align: right" title="Number of Shares, Granted">681,818</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zxLbRI9fsTVl" style="text-align: right" title="Weighted Average Grant-Date Fair Value per Award, Granted">0.33</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Vested</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zTyiTeCZ2w7d" style="text-align: right" title="Number of Shares, Vested">(170,455</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zyv3lLmUnMB9" style="text-align: right" title="Weighted Average Grant-Date Fair Value per Award, Vested">0.33</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Cancelled</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zNd7bBNcMIl3" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Shares, Cancelled">-</td><td style="text-align: left"></td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zLAC7tW0SEz6" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Grant-Date Fair Value per Award, Cancelled">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Non-vested as March 31, 2026</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zDVkCzw87QK9" style="text-align: right" title="Number of Shares, Non-vested Ending Balance">511,363</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z5rIN1KHTTFg" style="text-align: right" title="Weighted Average Grant-Date Fair Value per Award, Non-vested Ending Balance">0.33</td><td style="text-align: left"> </td></tr> </table> On January 1, 2026, the Company entered into restricted stock agreements with members of the Board of Directors of the Company. The Company granted <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20260101__20260101__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zUMMHv0JGXTf" title="Restricted stock awards granted">681,818 restricted stock awards with a fair market value of $<span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20260101__20260101__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_ztSUWwMBSO3l" title="Fair market value per share">0.33 per share. <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_dp_c20260101__20260101__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zhyvc5WMejM7" title="Vesting description">Such restricted stock vests as follows: 25% on the grant date in January 1, 2026, and 25% on April 1, 2026, July 1, 2026 and October 1, 2026. These awards vest immediately upon a change of control as defined in the agreements. For the three months ended March 31, 2026 and 2025, the Company recognized approximately $55,000 and $154,000 for restricted stock expenses recorded in general and administrative expenses on the statement of operation. As of March 31, 2026, there was $<span id="xdx_90E_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_do_c20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zZNDB7OB7q9h" title="Unrecognized compensation expense">170,000 of unrecognized compensation expense related to these awards.

11500000

P3Y

P5Y

257000

171000

1000000.0

P1Y10M24D

<p id="xdx_894_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_hus-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zgToQ3DVuAjk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">A summary of option activity for employees under the plans and changes during the three months ended March 31, 2026 is presented below: SCHEDULE OF STOCK OPTION ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number of Options</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted Averaged Exercise Price $</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Remaining Contractual Life (Years)</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Aggregate Intrinsic Options Value $</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Options outstanding at January 1, 2026</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zn1MKcAwAjqi" style="width: 11%; text-align: right" title="Number of Options Outstanding, Beginning Balance">6,032,175</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zsghd9gCgAb8" style="width: 11%; text-align: right" title="Weighted Averaged Exercise Price, Beginning Balance">1.15</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zxFeO8JyUKrb" title="Weighted Average Remaining Contractual Life (Years), Outstanding">8.13</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zW8WAKCI5S3k" style="width: 11%; text-align: right" title="Aggregate Intrinsic Options Value, Beginning Balance">-</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Granted during 2026</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z83dhwpfn3S6" style="text-align: right" title="Number of Options, Granted">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zWkukp0cZMX7" style="text-align: right" title="Weighted Averaged Exercise Price, Granted">-</td><td style="text-align: left"> </td><td style="font-style: normal"> </td> <td style="font-style: normal; text-align: left"> </td><td style="font-style: normal; text-align: right"> </td><td style="font-style: normal; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Exercised during 2026</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zdNyvXbsBQQd" style="text-align: right" title="Number of Options, Exercised">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zC34v1r36Sc" style="text-align: right" title="Weighted Averaged Exercise Price, Exercised">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Forfeited or expired during 2026</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zy7Ywsn5Fkj7" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options, Forfeited or expired">(32,175</td><td style="text-align: left">) </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zbLcd91EPtNe" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Averaged Exercise Price, Forfeited or expired">3.11</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Options outstanding March 31, 2026</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_ztCLEtWW53n3" style="text-align: right" title="Number of Options Outstanding, Ending Balance">6,000,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zj0Exvkynr5g" style="text-align: right" title="Weighted Averaged Exercise Price, Ending Balance">1.14</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zkgBlZsW6Imh" title="Weighted Average Remaining Contractual Life (Years), Outstanding">7.92</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zmVCFPLBWX7b" style="text-align: right" title="Aggregate Intrinsic Options Value, Ending Balance">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Exercisable, March 31, 2026</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zweHRLmeJP13" style="text-align: right" title="Number of Options, Exercisable">2,000,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zxuimYEGOkV9" style="text-align: right" title="Weighted Averaged Exercise Price, Exercisable">2.06</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zcUOekKFRRJe" title="Weighted Average Remaining Contractual Life (Years), Exercisable">5.92</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zKiRvlpR8CN6" style="text-align: right" title="Aggregate Intrinsic Options Value, Exercisable">-</td><td style="text-align: left"> </td></tr> </table>

6032175

1.15

P8Y1M17D

32175

3.11

6000000

1.14

P7Y11M1D

2000000

2.06

P5Y11M1D

<p id="xdx_891_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_hus-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zeYhNN7qdC36" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">A summary of option activity for non-employees under the plans and changes during the three months ended March 31, 2026 is presented below: SCHEDULE OF STOCK OPTION ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Number of Options</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"> </td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Weighted Averaged Exercise Price $</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"> </td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Weighted Average Remaining Contractual Life (Years)</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"> </td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Aggregate Intrinsic Options Value $</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; font-size: 10pt">Options outstanding at January 1, 2026</td><td style="width: 2%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zrsh4AgrWxP4" style="width: 11%; font-size: 10pt; text-align: right" title="Number of Options Outstanding, Beginning Balance">83,330</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 2%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zAYJ2vba0Qs4" style="width: 11%; font-size: 10pt; text-align: right" title="Weighted Averaged Exercise Price, Beginning Balance">1.59</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 2%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 11%; font-size: 10pt; text-align: right"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_ztbA6DJQgnvf" title="Weighted Average Remaining Contractual Life (Years), Outstanding">2.40</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 2%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zU03yCg5AOad" style="width: 11%; font-size: 10pt; text-align: right" title="Aggregate Intrinsic Options Value, Beginning Balance">-</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Granted during 2026</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zpfemakx2gs2" style="font-size: 10pt; text-align: right" title="Number of Options, Granted">-</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zA5AsBNyaVB3" style="font-size: 10pt; text-align: right" title="Weighted Averaged Exercise Price, Granted">-</td><td style="font-size: 10pt; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Exercised during 2026</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zt9A3XMr67k3" style="font-size: 10pt; text-align: right" title="Number of Options, Exercised">-</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zWNWtwEPUAug" style="font-size: 10pt; text-align: right" title="Weighted Averaged Exercise Price, Exercised">-</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Forfeited or expired during 2026</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zXttPLWafpo4" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Number of Options, Forfeited or expired">(16,666</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zCMSnpcNvDif" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Weighted Averaged Exercise Price, Forfeited or expired">3.94</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt">Options outstanding March 31, 2026</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zWWrBB4iWU79" style="font-size: 10pt; text-align: right" title="Number of Options Outstanding, Ending Balance">66,664</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z1aex6GRg0w" style="font-size: 10pt; text-align: right" title="Weighted Averaged Exercise Price, Ending Balance">1.00</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zGoZvj4mSTS8" title="Weighted Average Remaining Contractual Life (Years), Outstanding">2.70</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zWznmyYD1h7k" style="font-size: 10pt; text-align: right" title="Aggregate Intrinsic Options Value, Ending Balance">-</td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt">Exercisable, March 31, 2026</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zgKxVEVSzcYk" style="font-size: 10pt; text-align: right" title="Number of Options, Exercisable">49,994</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zihfrgQgl9h1" style="font-size: 10pt; text-align: right" title="Weighted Averaged Exercise Price, Exercisable">1.02</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_znvpWHuZrWve" title="Weighted Average Remaining Contractual Life (Years), Exercisable">2.35</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_znk2w9xOqVi8" style="font-size: 10pt; text-align: right" title="Aggregate Intrinsic Options Value, Exercisable">-</td><td style="font-size: 10pt; text-align: left"> </td></tr> </table> For the three months ended March 31, 2026, and 2025 Milestone Scientific recognized approximately $<span id="xdx_90F_eus-gaap--AllocatedShareBasedCompensationExpense_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zQd3BU00ch0f" title="Stock compensation expense">1,200 and $<span id="xdx_902_eus-gaap--AllocatedShareBasedCompensationExpense_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zdu93uDKICh5" title="Stock compensation expense">6,600 expense related to non-employee options, respectively. <p id="xdx_898_eus-gaap--DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_hus-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zghbHynJStN3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">A summary of restricted stock under the plans and changes during the three months ended March 31, 2026 is presented below: SCHEDULE OF RESTRICTED STOCK <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of Shares</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Grant-Date Fair Value per Award</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Non-vested as January 1, 2026</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_ziGZuPOWOvWk" style="width: 16%; text-align: right" title="Number of Shares, Non-vested Beginning Balance">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zmICkbdRPfAc" style="width: 16%; text-align: right" title="Weighted Average Grant-Date Fair Value per Award, Non-vested Beginning Balance">-</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zBHW16InGEm2" style="text-align: right" title="Number of Shares, Granted">681,818</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zxLbRI9fsTVl" style="text-align: right" title="Weighted Average Grant-Date Fair Value per Award, Granted">0.33</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Vested</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zTyiTeCZ2w7d" style="text-align: right" title="Number of Shares, Vested">(170,455</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zyv3lLmUnMB9" style="text-align: right" title="Weighted Average Grant-Date Fair Value per Award, Vested">0.33</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Cancelled</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zNd7bBNcMIl3" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Shares, Cancelled">-</td><td style="text-align: left"></td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zLAC7tW0SEz6" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Grant-Date Fair Value per Award, Cancelled">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Non-vested as March 31, 2026</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zDVkCzw87QK9" style="text-align: right" title="Number of Shares, Non-vested Ending Balance">511,363</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z5rIN1KHTTFg" style="text-align: right" title="Weighted Average Grant-Date Fair Value per Award, Non-vested Ending Balance">0.33</td><td style="text-align: left"> </td></tr> </table>

83330

1.59

P2Y4M24D

16666

3.94

66664

1.00

P2Y8M12D

49994

1.02

P2Y4M6D

1200

6600

<p id="xdx_898_eus-gaap--DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_hus-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zghbHynJStN3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">A summary of restricted stock under the plans and changes during the three months ended March 31, 2026 is presented below: SCHEDULE OF RESTRICTED STOCK <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of Shares</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Grant-Date Fair Value per Award</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Non-vested as January 1, 2026</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_ziGZuPOWOvWk" style="width: 16%; text-align: right" title="Number of Shares, Non-vested Beginning Balance">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zmICkbdRPfAc" style="width: 16%; text-align: right" title="Weighted Average Grant-Date Fair Value per Award, Non-vested Beginning Balance">-</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zBHW16InGEm2" style="text-align: right" title="Number of Shares, Granted">681,818</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zxLbRI9fsTVl" style="text-align: right" title="Weighted Average Grant-Date Fair Value per Award, Granted">0.33</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Vested</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zTyiTeCZ2w7d" style="text-align: right" title="Number of Shares, Vested">(170,455</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zyv3lLmUnMB9" style="text-align: right" title="Weighted Average Grant-Date Fair Value per Award, Vested">0.33</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Cancelled</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zNd7bBNcMIl3" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Shares, Cancelled">-</td><td style="text-align: left"></td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zLAC7tW0SEz6" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Grant-Date Fair Value per Award, Cancelled">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Non-vested as March 31, 2026</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zDVkCzw87QK9" style="text-align: right" title="Number of Shares, Non-vested Ending Balance">511,363</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z5rIN1KHTTFg" style="text-align: right" title="Weighted Average Grant-Date Fair Value per Award, Non-vested Ending Balance">0.33</td><td style="text-align: left"> </td></tr> </table>

681818

0.33

170455

0.33

511363

0.33

681818

0.33

Such restricted stock vests as follows: 25% on the grant date in January 1, 2026, and 25% on April 1, 2026, July 1, 2026 and October 1, 2026.

55000

154000

170000

NOTE 8 — INCOME TAXES The utilization of Milestone Scientific’s net operating losses may be subject to a substantial limitation due to the “change of ownership provisions” under Section 382 of the Internal Revenue Code and similar state provisions. Such limitation may result in the expiration of the net operating loss carry forwards before their utilization. Milestone Scientific has established a 100% valuation allowance for all its deferred tax assets due to uncertainty as to their future realization.

NOTE 9 — SEGMENT AND GEOGRAPHIC DATA Operating segments are reported in a manner consistent with the internal reporting provided to the chief operating decision maker. The chief operating decision maker, who is responsible for allocating resources and assessing performance of the operating segments, has been identified as the Chief Executive Officer (the “CODM”). The Company conducts its business through two reportable segments: Dental and Medical. These segments offer different products and services to different customer bases. The CODM assesses the financial performance of the segment and decides how to allocate resources based on Product sales, net, and operating income (loss). The Company provides general corporate services to its segments; however, these services are not considered when making operating decisions and assessing segment performance. These services are reported under “Corporate Services” below, and these include costs associated with executive management, investor relations, patents, trademarks, licensing agreements, new instruments developments, financing activities and public company compliance. The following tables present information about our reportable and operating segments for the three months ended March 31, 2026, and 2025: SCHEDULE OF REPORTABLE AND OPERATING SEGMENTS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" id="xdx_49E_20260101__20260331__srt--ConsolidationItemsAxis__us-gaap--CorporateNonSegmentMember_zttKa5FGIOya" style="border-bottom: Black 1pt solid; text-align: center">Corporate</td><td> </td><td> </td> <td colspan="2" id="xdx_490_20260101__20260331__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--DentalMember_z1Cpnl1C71o3" style="border-bottom: Black 1pt solid; text-align: center">Dental</td><td> </td><td> </td> <td colspan="2" id="xdx_491_20260101__20260331__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--MedicalMember_zquZouKD6Mj2" style="border-bottom: Black 1pt solid; text-align: center">Medical</td><td> </td><td> </td> <td colspan="2" id="xdx_49A_20260101__20260331__us-gaap--SubsegmentsAxis__custom--GrandTotalMember_z1pLjpjEhTHb" style="border-bottom: Black 1pt solid; text-align: center">Total</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="14" style="border-bottom: Black 1pt solid; text-align: center">2026</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Corporate</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Dental</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Medical</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Total</td><td> </td></tr> <tr id="xdx_405_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_zpvJVMwBDQQ9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left">Product sales, net</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">2,054,433</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">107,600</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">2,162,033</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--CostOfGoodsAndServicesSold_zUb28M6hKKMf" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Cost of products sold</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">584,581</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">13,428</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">598,009</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--GrossProfit_zIJvJD3CcVD7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Gross Margin</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,469,852</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">94,172</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,564,024</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--LaborAndRelatedExpense_zVRvmIcPW57a" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Salaries & employee benefits</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">177,249</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">419,448</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">228,305</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">825,002</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--AllocatedShareBasedCompensationExpense_zmkBcouI4EK6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Stock Compensation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">312,162</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">312,162</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--RoyaltyExpense_zHrp41MbWb8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Royalty expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">90,237</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,380</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">95,617</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_ecustom--WarehousingExpense_zZS9KLx4vVUa" style="vertical-align: bottom; background-color: White"> <td>Warehouse</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,282</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">131,095</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(2,600</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">129,777</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_ecustom--RegulatoryExpense_zlWYX1lYGMh3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Quality and Regulatory</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">88,806</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,486</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,312</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">94,604</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--MarketingExpense_zUeVbgjr3XE8" style="vertical-align: bottom; background-color: White"> <td>Marketing</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">31,390</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">36,367</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,975</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">73,732</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--OccupancyNet_ze52tElZcDo8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Rent & occupancy costs</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">19,733</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">17,066</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,666</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">47,465</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--ProfessionalFees_zIEOhE2Kojs5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Consultants and professional services fees</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">261,248</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">28,717</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">101,878</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">391,843</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--GeneralInsuranceExpense_zGwgOqPGQy9g" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Insurance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">41,826</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">46,092</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">40,620</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">128,538</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--TravelAndEntertainmentExpense_z3nwoB0Ubl0j" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Travel Expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">24,388</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25,327</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,810</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">60,525</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--DepreciationAndAmortization_zHhuuWVtUpwd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Depreciation and amortization expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">19,454</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">19,454</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--ResearchAndDevelopmentExpense_zRHIjQT83bm" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Research and development expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--SegmentReportingOtherItemAmount_zmcPTpId1ZT2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Other segment items</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">73,338</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">136,182</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">3,868</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">213,388</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--OperatingExpenses_zGJmPoPce7P6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total operating expenses</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,050,876</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">934,017</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">407,214</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">2,392,107</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--OperatingIncomeLoss_zGVQUJTx6gL" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Operating income (loss)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,050,876</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">535,835</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(313,042</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(828,083</td><td style="text-align: left">)</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" id="xdx_49F_20250101__20250331__srt--ConsolidationItemsAxis__us-gaap--CorporateNonSegmentMember_zo8thaFVS8vl" style="border-bottom: Black 1pt solid; text-align: center">Corporate</td><td> </td><td> </td> <td colspan="2" id="xdx_492_20250101__20250331__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--DentalMember_z6hWMv4PEftj" style="border-bottom: Black 1pt solid; text-align: center">Dental</td><td> </td><td> </td> <td colspan="2" id="xdx_49D_20250101__20250331__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--MedicalMember_zefXHIonqB24" style="border-bottom: Black 1pt solid; text-align: center">Medical</td><td> </td><td> </td> <td colspan="2" id="xdx_49B_20250101__20250331__us-gaap--SubsegmentsAxis__custom--GrandTotalMember_ze5E5bG9s4kh" style="border-bottom: Black 1pt solid; text-align: center">Total</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="14" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Corporate</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Dental</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Medical</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Total</td><td> </td></tr> <tr id="xdx_402_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_zKhyPz8D4GD5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left">Product sales, net</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">2,181,170</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">51,250</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">2,232,420</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--CostOfGoodsAndServicesSold_zayPxqmn1Cul" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Cost of products sold</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">584,896</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">89</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">584,985</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--GrossProfit_zLOJ2Yn82Os8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Gross Margin</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,596,274</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">51,161</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,647,435</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--LaborAndRelatedExpense_z4ZyqLEUGH2c" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Salaries & employee benefits</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">117,108</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">441,497</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">206,115</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">764,720</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--AllocatedShareBasedCompensationExpense_zzdoTooLA5bk" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Stock Compensation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">330,788</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">330,788</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--RoyaltyExpense_zkNfOpyiBX2f" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Royalty expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">109,928</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,563</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">112,491</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_ecustom--WarehousingExpense_zMZgskR8Up4b" style="vertical-align: bottom; background-color: White"> <td>Warehouse</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,205</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">112,314</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,773</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">122,292</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_ecustom--RegulatoryExpense_z4p40qKNeJq4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Quality and Regulatory</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">64,890</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">16,849</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,312</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">84,051</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--MarketingExpense_zW9NCSbLF78c" style="vertical-align: bottom; background-color: White"> <td>Marketing</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,261</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">83,629</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">24,321</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">112,211</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--OccupancyNet_zIwFdyuJwoNk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Rent & occupancy costs</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12,707</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12,521</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,826</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">33,054</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--ProfessionalFees_zFFWy1VfXaih" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Consultants and professional services fees</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,084,695</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">57,662</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">142,290</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,284,647</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--GeneralInsuranceExpense_z6c8b7C4z7O" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Insurance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">42,872</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">48,997</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">42,436</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">134,305</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--TravelAndEntertainmentExpense_zvT8m3UzyGe1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Travel Expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,473</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">31,668</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">29,961</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">66,102</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--DepreciationAndAmortization_zWEa7hPu2EKi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Depreciation and amortization expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">19,440</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">19,440</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--ResearchAndDevelopmentExpense_z9mykq3FC8a4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Research and development expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">364,807</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,313</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">369,120</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--SegmentReportingOtherItemAmount_zSPR1D7z1094" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Other segment items</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">73,518</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">137,048</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,501</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">212,067</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--OperatingExpenses_zqmoA404AhY2" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total operating expenses</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,755,957</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,416,920</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">472,411</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">3,645,288</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--OperatingIncomeLoss_zBZp9Fsab6Rc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Operating income (loss)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(1,755,957</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">179,354</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(421,250</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(1,997,853</td><td style="text-align: left">)</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td colspan="17" style="border-bottom: Black 1pt solid; text-align: center">March 31, 2026</td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Dental</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Medical</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Corporate</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%; text-align: left; padding-bottom: 1pt">Total Assets</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--Assets_iI_c20260331__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--DentalSegmentMember_zYkEtbtRlIri" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Total assets">5,454,090</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--Assets_iI_c20260331__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--MedicalSegmentMember_zTPuGuOn0X28" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Total assets">360,199</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--Assets_iI_c20260331__srt--ConsolidationItemsAxis__us-gaap--CorporateNonSegmentMember_zK82wQGwf4w5" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Total assets">2,148,665</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--Assets_iI_c20260331_zt3XJbIw58wa" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Total assets">7,962,954</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_eus-gaap--Assets_iI_c20260331__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--DentalSegmentMember_zp5alq6i22Je" style="border-bottom: Black 2.5pt double; text-align: right" title="Total assets">5,454,090</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_986_eus-gaap--Assets_iI_c20260331__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--MedicalSegmentMember_zHezcW2X69Ld" style="border-bottom: Black 2.5pt double; text-align: right" title="Total assets">360,199</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98B_eus-gaap--Assets_iI_c20260331__srt--ConsolidationItemsAxis__us-gaap--CorporateNonSegmentMember_zl59TdCYaedd" style="border-bottom: Black 2.5pt double; text-align: right" title="Total assets">2,148,665</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_982_eus-gaap--Assets_iI_c20260331_zh9z8UUQfPfe" style="border-bottom: Black 2.5pt double; text-align: right" title="Total assets">7,962,954</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td colspan="17" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2025</td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Dental</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Medical</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Corporate</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%; text-align: left; padding-bottom: 1pt">Total Assets</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--Assets_iI_c20251231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--DentalSegmentMember_zge0nPejdYxk" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Total assets">5,861,323</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--Assets_iI_c20251231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--MedicalSegmentMember_zvZp8YZBWOHa" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Total assets">394,267</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--Assets_iI_c20251231__srt--ConsolidationItemsAxis__us-gaap--CorporateNonSegmentMember_z1kVvuMc04jb" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Total assets">1,550,839</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--Assets_iI_c20251231_zZdkNWOOwsck" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Total assets">7,806,429</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98A_eus-gaap--Assets_iI_c20251231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--DentalSegmentMember_zVfPbPrXed2" style="border-bottom: Black 2.5pt double; text-align: right" title="Total assets">5,861,323</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_984_eus-gaap--Assets_iI_c20251231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--MedicalSegmentMember_zHA4MmjUseaf" style="border-bottom: Black 2.5pt double; text-align: right" title="Total assets">394,267</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_989_eus-gaap--Assets_iI_c20251231__srt--ConsolidationItemsAxis__us-gaap--CorporateNonSegmentMember_zML4VpMoXgq8" style="border-bottom: Black 2.5pt double; text-align: right" title="Total assets">1,550,839</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_989_eus-gaap--Assets_iI_c20251231_zjLltsrDKXql" style="border-bottom: Black 2.5pt double; text-align: right" title="Total assets">7,806,429</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

The following tables present information about our reportable and operating segments for the three months ended March 31, 2026, and 2025: SCHEDULE OF REPORTABLE AND OPERATING SEGMENTS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" id="xdx_49E_20260101__20260331__srt--ConsolidationItemsAxis__us-gaap--CorporateNonSegmentMember_zttKa5FGIOya" style="border-bottom: Black 1pt solid; text-align: center">Corporate</td><td> </td><td> </td> <td colspan="2" id="xdx_490_20260101__20260331__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--DentalMember_z1Cpnl1C71o3" style="border-bottom: Black 1pt solid; text-align: center">Dental</td><td> </td><td> </td> <td colspan="2" id="xdx_491_20260101__20260331__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--MedicalMember_zquZouKD6Mj2" style="border-bottom: Black 1pt solid; text-align: center">Medical</td><td> </td><td> </td> <td colspan="2" id="xdx_49A_20260101__20260331__us-gaap--SubsegmentsAxis__custom--GrandTotalMember_z1pLjpjEhTHb" style="border-bottom: Black 1pt solid; text-align: center">Total</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="14" style="border-bottom: Black 1pt solid; text-align: center">2026</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Corporate</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Dental</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Medical</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Total</td><td> </td></tr> <tr id="xdx_405_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_zpvJVMwBDQQ9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left">Product sales, net</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">2,054,433</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">107,600</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">2,162,033</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--CostOfGoodsAndServicesSold_zUb28M6hKKMf" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Cost of products sold</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">584,581</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">13,428</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">598,009</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--GrossProfit_zIJvJD3CcVD7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Gross Margin</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,469,852</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">94,172</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,564,024</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--LaborAndRelatedExpense_zVRvmIcPW57a" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Salaries & employee benefits</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">177,249</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">419,448</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">228,305</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">825,002</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--AllocatedShareBasedCompensationExpense_zmkBcouI4EK6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Stock Compensation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">312,162</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">312,162</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--RoyaltyExpense_zHrp41MbWb8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Royalty expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">90,237</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,380</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">95,617</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_ecustom--WarehousingExpense_zZS9KLx4vVUa" style="vertical-align: bottom; background-color: White"> <td>Warehouse</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,282</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">131,095</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(2,600</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">129,777</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_ecustom--RegulatoryExpense_zlWYX1lYGMh3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Quality and Regulatory</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">88,806</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,486</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,312</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">94,604</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--MarketingExpense_zUeVbgjr3XE8" style="vertical-align: bottom; background-color: White"> <td>Marketing</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">31,390</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">36,367</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,975</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">73,732</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--OccupancyNet_ze52tElZcDo8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Rent & occupancy costs</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">19,733</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">17,066</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,666</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">47,465</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--ProfessionalFees_zIEOhE2Kojs5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Consultants and professional services fees</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">261,248</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">28,717</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">101,878</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">391,843</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--GeneralInsuranceExpense_zGwgOqPGQy9g" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Insurance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">41,826</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">46,092</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">40,620</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">128,538</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--TravelAndEntertainmentExpense_z3nwoB0Ubl0j" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Travel Expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">24,388</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25,327</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,810</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">60,525</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--DepreciationAndAmortization_zHhuuWVtUpwd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Depreciation and amortization expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">19,454</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">19,454</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--ResearchAndDevelopmentExpense_zRHIjQT83bm" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Research and development expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--SegmentReportingOtherItemAmount_zmcPTpId1ZT2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Other segment items</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">73,338</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">136,182</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">3,868</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">213,388</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--OperatingExpenses_zGJmPoPce7P6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total operating expenses</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,050,876</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">934,017</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">407,214</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">2,392,107</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--OperatingIncomeLoss_zGVQUJTx6gL" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Operating income (loss)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,050,876</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">535,835</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(313,042</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(828,083</td><td style="text-align: left">)</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" id="xdx_49F_20250101__20250331__srt--ConsolidationItemsAxis__us-gaap--CorporateNonSegmentMember_zo8thaFVS8vl" style="border-bottom: Black 1pt solid; text-align: center">Corporate</td><td> </td><td> </td> <td colspan="2" id="xdx_492_20250101__20250331__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--DentalMember_z6hWMv4PEftj" style="border-bottom: Black 1pt solid; text-align: center">Dental</td><td> </td><td> </td> <td colspan="2" id="xdx_49D_20250101__20250331__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--MedicalMember_zefXHIonqB24" style="border-bottom: Black 1pt solid; text-align: center">Medical</td><td> </td><td> </td> <td colspan="2" id="xdx_49B_20250101__20250331__us-gaap--SubsegmentsAxis__custom--GrandTotalMember_ze5E5bG9s4kh" style="border-bottom: Black 1pt solid; text-align: center">Total</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="14" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Corporate</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Dental</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Medical</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Total</td><td> </td></tr> <tr id="xdx_402_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_zKhyPz8D4GD5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left">Product sales, net</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">2,181,170</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">51,250</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">2,232,420</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--CostOfGoodsAndServicesSold_zayPxqmn1Cul" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Cost of products sold</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">584,896</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">89</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">584,985</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--GrossProfit_zLOJ2Yn82Os8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Gross Margin</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,596,274</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">51,161</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,647,435</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--LaborAndRelatedExpense_z4ZyqLEUGH2c" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Salaries & employee benefits</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">117,108</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">441,497</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">206,115</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">764,720</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--AllocatedShareBasedCompensationExpense_zzdoTooLA5bk" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Stock Compensation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">330,788</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">330,788</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--RoyaltyExpense_zkNfOpyiBX2f" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Royalty expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">109,928</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,563</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">112,491</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_ecustom--WarehousingExpense_zMZgskR8Up4b" style="vertical-align: bottom; background-color: White"> <td>Warehouse</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,205</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">112,314</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,773</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">122,292</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_ecustom--RegulatoryExpense_z4p40qKNeJq4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Quality and Regulatory</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">64,890</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">16,849</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,312</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">84,051</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--MarketingExpense_zW9NCSbLF78c" style="vertical-align: bottom; background-color: White"> <td>Marketing</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,261</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">83,629</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">24,321</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">112,211</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--OccupancyNet_zIwFdyuJwoNk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Rent & occupancy costs</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12,707</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12,521</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,826</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">33,054</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--ProfessionalFees_zFFWy1VfXaih" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Consultants and professional services fees</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,084,695</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">57,662</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">142,290</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,284,647</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--GeneralInsuranceExpense_z6c8b7C4z7O" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Insurance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">42,872</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">48,997</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">42,436</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">134,305</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--TravelAndEntertainmentExpense_zvT8m3UzyGe1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Travel Expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,473</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">31,668</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">29,961</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">66,102</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--DepreciationAndAmortization_zWEa7hPu2EKi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Depreciation and amortization expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">19,440</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">19,440</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--ResearchAndDevelopmentExpense_z9mykq3FC8a4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Research and development expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">364,807</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,313</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">369,120</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--SegmentReportingOtherItemAmount_zSPR1D7z1094" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Other segment items</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">73,518</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">137,048</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,501</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">212,067</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--OperatingExpenses_zqmoA404AhY2" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total operating expenses</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,755,957</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,416,920</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">472,411</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">3,645,288</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--OperatingIncomeLoss_zBZp9Fsab6Rc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Operating income (loss)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(1,755,957</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">179,354</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(421,250</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(1,997,853</td><td style="text-align: left">)</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td colspan="17" style="border-bottom: Black 1pt solid; text-align: center">March 31, 2026</td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Dental</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Medical</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Corporate</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%; text-align: left; padding-bottom: 1pt">Total Assets</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--Assets_iI_c20260331__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--DentalSegmentMember_zYkEtbtRlIri" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Total assets">5,454,090</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--Assets_iI_c20260331__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--MedicalSegmentMember_zTPuGuOn0X28" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Total assets">360,199</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--Assets_iI_c20260331__srt--ConsolidationItemsAxis__us-gaap--CorporateNonSegmentMember_zK82wQGwf4w5" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Total assets">2,148,665</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--Assets_iI_c20260331_zt3XJbIw58wa" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Total assets">7,962,954</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_eus-gaap--Assets_iI_c20260331__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--DentalSegmentMember_zp5alq6i22Je" style="border-bottom: Black 2.5pt double; text-align: right" title="Total assets">5,454,090</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_986_eus-gaap--Assets_iI_c20260331__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--MedicalSegmentMember_zHezcW2X69Ld" style="border-bottom: Black 2.5pt double; text-align: right" title="Total assets">360,199</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98B_eus-gaap--Assets_iI_c20260331__srt--ConsolidationItemsAxis__us-gaap--CorporateNonSegmentMember_zl59TdCYaedd" style="border-bottom: Black 2.5pt double; text-align: right" title="Total assets">2,148,665</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_982_eus-gaap--Assets_iI_c20260331_zh9z8UUQfPfe" style="border-bottom: Black 2.5pt double; text-align: right" title="Total assets">7,962,954</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td colspan="17" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2025</td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Dental</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Medical</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Corporate</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%; text-align: left; padding-bottom: 1pt">Total Assets</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--Assets_iI_c20251231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--DentalSegmentMember_zge0nPejdYxk" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Total assets">5,861,323</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--Assets_iI_c20251231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--MedicalSegmentMember_zvZp8YZBWOHa" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Total assets">394,267</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--Assets_iI_c20251231__srt--ConsolidationItemsAxis__us-gaap--CorporateNonSegmentMember_z1kVvuMc04jb" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Total assets">1,550,839</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--Assets_iI_c20251231_zZdkNWOOwsck" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Total assets">7,806,429</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98A_eus-gaap--Assets_iI_c20251231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--DentalSegmentMember_zVfPbPrXed2" style="border-bottom: Black 2.5pt double; text-align: right" title="Total assets">5,861,323</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_984_eus-gaap--Assets_iI_c20251231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--MedicalSegmentMember_zHA4MmjUseaf" style="border-bottom: Black 2.5pt double; text-align: right" title="Total assets">394,267</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_989_eus-gaap--Assets_iI_c20251231__srt--ConsolidationItemsAxis__us-gaap--CorporateNonSegmentMember_zML4VpMoXgq8" style="border-bottom: Black 2.5pt double; text-align: right" title="Total assets">1,550,839</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_989_eus-gaap--Assets_iI_c20251231_zjLltsrDKXql" style="border-bottom: Black 2.5pt double; text-align: right" title="Total assets">7,806,429</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

2054433

107600

2162033

584581

13428

598009

1469852

94172

1564024

177249

419448

228305

825002

312162

90237

5380

95617

1282 131095 -2600 129777 88806 3486 2312 94604

31390

36367

5975

73732

19733

17066

10666

47465

261248

28717

101878

391843

41826

46092

40620

128538

24388

25327

10810

60525

19454

73338

136182

3868

213388

1050876

934017

407214

2392107

-1050876

535835

-313042

-828083

2181170

51250

2232420

584896

584985

1596274

51161

1647435

117108

441497

206115

764720

330788

109928

2563

112491

1205 112314 8773 122292 64890 16849 2312 84051

4261

83629

24321

112211

12707

12521

7826

33054

1084695

57662

142290

1284647

42872

48997

42436

134305

4473

31668

29961

66102

19440

364807

4313

369120

73518

137048

1501

212067

1755957

1416920

472411

3645288

-1755957

179354

-421250

-1997853

5454090

360199

2148665

7962954

5454090

360199

2148665

7962954

5861323

394267

1550839

7806429

5861323

394267

1550839

7806429

NOTE 10 – CONCENTRATIONS Milestone Scientific has informal arrangements with third-party U.S. manufacturers of the STA devices and epidural instruments pursuant to which they manufacture these products under specific purchase orders that contain advance payments for long lead items for production. Advances on contracts have been classified as current at March 31, 2026 and December 31, 2025. The termination of the manufacturing relationship with any of these manufacturers could have a material adverse effect on Milestone Scientific’s ability to produce and sell its products. Although alternate sources of supply exist, and new manufacturing relationships could be established, Milestone Scientific would need to recover its existing tools or have new tools produced. Establishment of new manufacturing relationships could involve significant expense and delay. Any curtailment or interruption of the supply, because of the termination of such a relationship, would have a material adverse effect on Milestone Scientific’s financial condition, business, and results of operations. On January 3, 2023, the Company launched an E-Commerce platform selling and shipping STA Single Tooth Anesthesia System® (STA) and handpieces directly to dental offices and dental groups within the U.S. For the three months ended March 31, 2026, E-Commerce accounted for <span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20260101__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--ECommerceMember_zHQOYn6T3un5" title="Concentration risk, percentage">51% of net product sales, and <span id="xdx_907_ecustom--NumberOfDistributors_do_uInteger_c20260101__20260331__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--DistributorOneMember_zdDxmyyx9cxh" title="Number of distributors">no international distributors accounted for over 10% of net product sales. For the three months ended March 31, 2025, E-commerce accounted for <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20250101__20250331__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--ECommerceMember_znomL6s8t3Sb" title="Concentration risk, percentage">50% of net product sales, and <span id="xdx_90A_ecustom--NumberOfDistributors_dc_uInteger_c20250101__20250331__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--DistributorOneMember_zHJmvdXAPVv5" title="Number of distributors">one international distributor accounted for <span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20250101__20250331__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--DistributorOneMember_zq6mnPZN9Kjg" title="Concentration risk, percentage">13% of net product sales. The Company had <span id="xdx_907_ecustom--NumberOfDistributors_dc_uInteger_c20260101__20260331__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_zTzKgx0yk9d" title="Number of distributors">three distributors that accounted for <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20260101__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--DistributorOneMember_zgsdwB5d4dfj" title="Concentration risk, percentage">22%, <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20260101__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--DistributorTwoMember_zfvWMsS88Mec" title="Concentration risk, percentage">17%, <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20260101__20260331__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--DistributorThreeMember_z6yOHYEC5w36" title="Concentration risk, percentage">12% of accounts receivable, respectively, for the three months ended March 31, 2026. The Company had <span id="xdx_905_ecustom--NumberOfDistributors_dc_uInteger_c20250101__20250331__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_zZWvQj5CYg7g" title="Number of distributors">three distributors that accounted for <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20250101__20251231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--DistributorOneMember_zKcSIhgJ02e8" title="Concentration risk, percentage">32%, <span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20250101__20251231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--DistributorTwoMember_zPLQpUXu51Zi" title="Concentration risk, percentage">21% and <span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20250101__20251231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--DistributorThreeMember_zcqCDPU3OAgi" title="Concentration risk, percentage">11% of accounts receivable, respectively as of December 31, 2025. As of March 31, 2026, the Company had <span id="xdx_90E_ecustom--NumberOfSuppliers_dc_uInteger_c20260101__20260331__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember_zIRLYRHKxCHl" title="Number of suppliers">four suppliers that accounted for <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20260101__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierOneMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_z8IfrxmmQTIb" title="Concentration risk, percentage">25%, <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20260101__20260331__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__srt--MajorCustomersAxis__custom--SupplierTwoMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zSHgzFxc8mIf" title="Concentration risk, percentage">19%, <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20260101__20260331__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__srt--MajorCustomersAxis__custom--SupplierThreeMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zBMtp4YGNgNc" title="Concentration risk, percentage">12% and <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20260101__20260331__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__srt--MajorCustomersAxis__custom--SupplierFourMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zyMBQh5B0Z1k" title="Concentration risk, percentage">11%, respectively, of accounts payable and accounts payable, related party. The Company had <span id="xdx_903_ecustom--NumberOfSuppliers_dc_uInteger_c20250101__20251231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember_z1xV80s601B3" title="Number of suppliers">three suppliers that accounted for <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20250101__20251231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__srt--MajorCustomersAxis__custom--SupplierOneMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_z0XK44Abcv3i" title="Concentration risk, percentage">38%, <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20250101__20251231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__srt--MajorCustomersAxis__custom--SupplierTwoMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zHEd3icVQBN7" title="Concentration risk, percentage">22%, and <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20250101__20251231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__srt--MajorCustomersAxis__custom--SupplierThreeMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zX7u3pvCqKDj" title="Concentration risk, percentage">10%, respectively of accounts payable and accounts payable, related to the party as of December 31, 2025.

0.51

0.50

0.13

0.22

0.17

0.12

0.32

0.21

0.11

0.25

0.19

0.12

0.11

0.38

0.22

0.10

NOTE 11 — RELATED PARTY TRANSACTIONS United Systems In June 2021, the Company entered into a ten-year supply agreement with United Systems, the principal supplier of its handpieces, for the manufacture and supply of handpieces. Pursuant to the agreement, the Company procures products under specific purchase orders but without minimum purchase commitments. Purchases from this supplier were approximately $<span id="xdx_90E_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_c20260101__20260331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UnitedSystemsMember_zASraPHJCe0b" title="Purchases from supplier">249,000 and $<span id="xdx_907_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_c20250101__20250331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UnitedSystemsMember_z4AvmBa45Obf" title="Purchases from supplier">487,000 for the three months ended March 31, 2026 and 2025, respectively. As of March 31, 2026, and December 31, 2025, Milestone Scientific owed this supplier approximately $<span id="xdx_901_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_iI_c20260331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UnitedSystemsMember_zJVWiNucifN" title="Amounts owed">801,000 and $<span id="xdx_905_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_iI_c20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UnitedSystemsMember_zjdZ8ZDvplqi" title="Amounts owed">1,100,000, respectively, which is included in accounts payable and accrued expenses related party on the unaudited condensed consolidated balance sheets. Director of Clinical Affairs The Company pays royalties to its Director of Clinical Affairs pursuant to existing royalty arrangements related to certain Company products. Royalty expense paid to the Director of Clinical Affairs totaled approximately $96,000 and $112,000 for the three months ended March 31, 2026 and 2025, respectively. In addition, the Company paid consulting fees to the Director of Clinical Affairs totaling approximately $<span id="xdx_905_eus-gaap--ProfessionalFees_c20260101__20260331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorClinicalAffairMember_zhTtfTNYe2z1" title="Consultants and professional services fees">25,000 and $<span id="xdx_900_eus-gaap--ProfessionalFees_c20250101__20250331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorClinicalAffairMember_z6q6KlKzjat3" title="Consultants and professional services fees">39,000 for the three months ended March 31, 2026 and 2025, respectively. As of March 31, 2026 and December 31, 2025, accrued but unpaid royalties owed to the Director of Clinical Affairs were approximately $<span id="xdx_903_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_iI_c20260331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorClinicalAffairMember_z4FGNkNg2cMc" title="Accounts payable and accrued liabilities, current">384,000 and $<span id="xdx_90B_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_iI_c20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorClinicalAffairMember_zYaOaGtOaIXd" title="Accounts payable and accrued liabilities, current">289,000, respectively. These amounts are included in accounts payable related party and accrued expenses related party in the Company’s consolidated balance sheets. Directors Leonard Osser As part of the Company’s succession planning, on April 6, 2021, Mr. Osser entered into an agreement with the Company (the “Succession Agreement”) pursuant to which he agreed to restructure certain of his existing arrangements with the Company to in anticipation of providing broader executive support beyond the Company’s Chinese operations and, so that upon stepping down as Interim Chief Executive Officer, he would agree to assume the role of Vice Chairman of the Board. In connection with the Succession Agreement: <table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.25in; text-align: justify"> </td> <td style="width: 0.25in; text-align: justify">●</td> <td style="text-align: justify">Compensation under Mr. Osser’s July 2017 Employment Agreement (the “Osser Employment Agreement”) was reduced by $<span id="xdx_906_eus-gaap--IncreaseDecreaseInDeferredCompensation_di_c20170731__20170731__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrOsserViceChairmanOfBoardMember_ziuECRdy89oh" title="Increase decrease in deferred compensation">100,000 to $<span id="xdx_900_ecustom--EmploymentAgreementBaseCompensation_c20170731__20170731__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrOsserViceChairmanOfBoardMember_z2tTrWOiu2U4" title="Employment agreement, base compensation">200,000, with the reduction split equally between cash compensation and equity compensation.</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"> </td> <td style="text-align: justify">●</td> <td style="text-align: justify"> Compensation under his July 2017 Consulting Agreement (the “Osser Consulting Agreement”) was increased by $<span id="xdx_903_eus-gaap--IncreaseDecreaseInDeferredCompensation_c20170731__20170731__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrOsserViceChairmanOfBoardMember_zoCHkajyTCD5" title="Increase (decrease) in compensation">100,000 to $<span id="xdx_906_ecustom--EmploymentAgreementBaseCompensation_c20170731__20170731__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrOsserViceChairmanOfBoardMember_zBEGjWH1pPfl" title="Employment agreement, base compensation">200,000, also split equally between cash and equity compensation. The equity component shifted from the Osser Employment Agreement to the Osser Consulting Agreement. </td></tr> </table> On May 19, 2021, Mr. Osser stepped down as Interim Chief Executive Officer and formally assumed the role as Vice Chairman. Compensation under the Osser Employment Agreement and Osser Consulting Agreement is payable for <span id="xdx_90E_eus-gaap--DeferredCompensationArrangementWithIndividualMaximumContractualTerm1_dtY_c20210519__20210519__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrOsserViceChairmanOfBoardMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zUsTEtbiauUd" title="Compensation term"><span id="xdx_90F_eus-gaap--DeferredCompensationArrangementWithIndividualMaximumContractualTerm1_dtY_c20210519__20210519__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrOsserViceChairmanOfBoardMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zOhkEKTOP399" title="Compensation term">9.5 years from May 19, 2021. For each of the three months ended March 31, 2026 and 2025, the Company recorded: <table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.25in; text-align: justify"> </td> <td style="width: 0.25in; text-align: justify">●</td> <td style="text-align: justify">$<span id="xdx_90A_eus-gaap--DeferredCompensationArrangementWithIndividualCompensationExpense_c20260101__20260331__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrOsserViceChairmanOfBoardMember_zjuc8xdSSzVd" title="Consulting expense">50,000 of expenses related to the Osser Employment Agreement; and</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"> </td> <td style="text-align: justify">●</td> <td style="text-align: justify">$<span id="xdx_906_eus-gaap--DeferredCompensationArrangementWithIndividualCompensationExpense_c20260101__20260331__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrOsserViceChairmanOfBoardMember_zEBmfgtuznDc" title="Consulting expense">50,000 of expenses related to the Osser Consulting Agreement.</td></tr> </table> If the Company terminates Mr. Osser’s employment without cause (other than due to death or disability), or if Mr. Osser terminates his employment for good reason (each as defined in the applicable agreement), he is entitled to receive, in a lump sum, an amount equal to the aggregate present value (determined in accordance with Section 280G(d)(4) of the Internal Revenue Code) of all compensation payable from the termination date through the remainder of the employment term. Vice Chairman Appointment and Option Grant Upon stepping down as Interim Chief Executive Officer, Mr. Osser assumed the role of Vice Chairman of the Board on May 19, 2021. In connection with his new role as Vice Chairman and in exchange for his ongoing consulting services, Mr. Osser was granted options to purchase <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210519__20210519__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrOsserViceChairmanOfBoardMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zlgv5ipD61N8" title="Options granted to purchase common stock">2,000,000 shares of common stock at fair market value on the May 19, 2021. These options vest over five <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtY_c20210519__20210519__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrOsserViceChairmanOfBoardMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zthEkkvGeXX2" title="Options vesting period">5 years and expire ten <span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dtY_c20210519__20210519__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrOsserViceChairmanOfBoardMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zXGdXRvgwmlk" title="Options exercisable period">10 years from the date of grant. Mr. Osser subsequently resigned from the Board of Directors on November 7, 2025. Beneficial Ownership Mr. Osser beneficially owns <span id="xdx_906_eus-gaap--InvestmentOwnedBalanceShares_iI_c20260331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrOsserViceChairmanOfBoardMember_zdznM86GBj64" title="Shares issued and owned">2,844,028 shares of the Company’s common stock and is entitled to receive an additional <span id="xdx_90B_ecustom--SharesToBeIssuedAtEmploymentTermination_c20260101__20260331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrOsserViceChairmanOfBoardMember_zSOYI34TbNw2" title="Shares to be issued at employment termination">3,221,786 shares upon termination of his Employment Agreement. Dr. D. Demesmin, Director As of February 2024, the University Pain Medicine Center (STEMMEE), of which Dr. D. Demesmin, a member of the Company’s Board of Directors, serves as Chief Executive Officer, agreed to purchase products from the Company under terms and conditions consistent with those offered to other medical pain clinics in the United States. STEMMEE purchased medical products totaling approximately $<span id="xdx_905_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20260101__20260331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UniversityPainMedicineCenterSTEMMEEMember_z9cljId3qCT2" title="Related party transaction, amounts of transaction"><span id="xdx_905_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20250101__20250331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UniversityPainMedicineCenterSTEMMEEMember_zVQcuWyib6n7" title="Related party transaction, amounts of transaction">6,000 for each of the three months ended March 31, 2026 and 2025. The company was owed approximately $ <span id="xdx_900_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_c20260101__20260331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UniversityPainMedicineCenterSTEMMEEMember_zucVTLdswTm1" title="Related party transaction, amounts of transaction owed">22,300 and $ <span id="xdx_90D_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UniversityPainMedicineCenterSTEMMEEMember_zbqWfZZGQxR2" title="Related party transaction, amounts of transaction owed">25,500 as of March 31, 2026 and December 31, 2025 respectively. These amounts are regarded in related party accounts receivable. Arjan J. Haverhals, Director The Company entered into a consulting agreement with Jan Adriaan (Arjan) Haverhals (the “Haverhals Consulting Agreement”), effective January 1, 2025. The Haverhals Consulting Agreement continues for an indefinite term unless terminated in accordance with its terms. Either party may terminate the Haverhals Consulting Agreement upon 90 days’ prior written notice. The Company may terminate the Haverhals Consulting Agreement upon 30 days’ prior written notice in the event of Mr. Haverhals’ inability to provide services. Under the Haverhals Consulting Agreement, Mr. Haverhals is entitled to receive consulting fees at an annual rate of $350,000, payable monthly in arrears. For 2025, compensation was structured as follows: <table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">·</td><td style="text-align: justify">$<span id="xdx_90E_ecustom--PaymentsForConsultingServices_c20250101__20250331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JanAdriaanArjanHaverhalsMember_ztPfyURRovK5" title="Consulting fee payable">150,000 for the first calendar quarter of 2025; and</td></tr></table> <table cellpadding="0" cellspacing="0" style="width: 100%; font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">·</td><td style="text-align: justify">$<span id="xdx_903_ecustom--PaymentsForConsultingServices_c20250401__20250630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JanAdriaanArjanHaverhalsMember_zKMi5uZXYn6a" title="Consulting fee payable"><span id="xdx_904_ecustom--PaymentsForConsultingServices_c20250701__20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JanAdriaanArjanHaverhalsMember_z1jNHv06WOmi" title="Consulting fee payable"><span id="xdx_908_ecustom--PaymentsForConsultingServices_c20251001__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JanAdriaanArjanHaverhalsMember_zzdSye2XEm4" title="Consulting fee payable">67,000 for each subsequent calendar quarter of 2025.</td></tr></table> The Company recorded consulting expense of approximately $<span id="xdx_905_ecustom--PaymentsForConsultingServices_c20250101__20250331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JanAdriaanArjanHaverhalsMember_zyDfz9q3uRsh" title="Consulting fee payable">150,000 for the three months ended March 31, 2025 related to the Haverhals Consulting Agreement. No expense was recorded for the three months ended March 31, 2026. Mr. Haverhals is entitled to reimbursement of reasonable expenses incurred in connection with the performance of his services. He serves as an independent contractor and is not eligible for Company-provided employee benefits, including health or accident insurance, life insurance, paid sick leave, or paid vacation. In connection with the Haverhals Consulting Agreement, Mr. Haverhals entered into the Company’s standard form of non-disclosure, non-solicitation, non-competition, and invention assignment agreement. As of March 31, 2026, and December 31, 2025, the Company owed Mr. Haverhals approximately $<span id="xdx_909_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_c20260101__20260331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ArjanJHaverhalsAndDirectorMember_zuNxa1OehZme" title="Related party transaction, amounts of transaction owed">0 and $<span id="xdx_908_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ArjanJHaverhalsAndDirectorMember_zN4cK024nQTb" title="Related party transaction, amounts of transaction owed">89,000, respectively, under the Haverhals Consulting Agreement, which is included in accounts payable—related party in the Company’s condensed consolidated balance sheets. Subsequent to December 31, 2025, Mr. Haverhals agreed to waive approximately $66,000 of amounts payable to him, which had previously been included in accounts payable—related party. Pursuant to the Haverhals Consulting Agreement, Mr. Haverhals is entitled to receive 912,736 shares of the Company’s common stock six months following his resignation as Chief Executive Officer, subject to the terms of the Haverhals Consulting Agreement. As of March 31, 2026, such shares had not been issued. At the Company’s Annual Meeting of Stockholders held on December 18, 2025, Mr. Haverhals was not re-elected to the Board of Directors, and his term as a director expired at the conclusion of the Annual Meeting. April 2025 Convertible Notes On April 9, 2025, the Company issued a series of promissory notes in the aggregate amount of $<span id="xdx_90B_eus-gaap--NotesPayable_iI_c20250409__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrNealGoldmanMsBenedettaCasamentoAndDrDidierDemesminMember_zjXCzhZIRoK7" title="Promissory notes">800,000 to Mr. Neal Goldman, Ms. Benedetta Casamento, and Dr. Didier Demesmin, each of whom is a director of the Company. The notes are due April 9, 2028 and bear interest at the annual rate of prime less <span id="xdx_90D_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20250409__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrNealGoldmanMsBenedettaCasamentoAndDrDidierDemesminMember_zRXVWLdPnHrh" title="Interest rate">2.50%, payable annually. All principal and interest shall be payable in cash and/or shares of common stock at the sole discretion of the Company. The notes are convertible into shares of common stock by the holder at any time and by the Company at maturity. If the Company sells equity securities for gross proceeds in excess of $<span id="xdx_90C_ecustom--DebtInstrumentEquitySecuritiesIssuanceGrossProceedsBenchmark_c20250409__20250409__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrNealGoldmanMsBenedettaCasamentoAndDrDidierDemesminMember_zhH0VmFNIuT2" title="Gross proceeds from sale of equity securities">4,000,000, the holders may request repayment of their note in either cash, shares of common stock or a combination of cash and shares; provided, that the holders would then be entitled to receive only so much cash as the net proceeds to the Company in such sale of equity securities, after payment of other indebtedness and other uses (other than working capital) specified as a use of the proceeds in the relevant offering or disclosure documentation, shall be in excess of $<span id="xdx_909_ecustom--DebtInstrumentEquitySecuritiesIssuanceGrossProceedsBenchmark_c20250409__20250409__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrNealGoldmanMsBenedettaCasamentoAndDrDidierDemesminMember_zBjr4Z3hoyd4" title="Gross proceeds from sale of equity securities">4,000,000. Upon a liquidation event of the Company, as defined in the notes which includes a sale of the Company or assets, a merger, reorganization or combination transaction where the shareholders before the transaction own less than <span id="xdx_908_eus-gaap--SaleOfStockPercentageOfOwnershipBeforeTransaction_pid_dp_uPure_c20250409__20250409__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrNealGoldmanMsBenedettaCasamentoAndDrDidierDemesminMember_zSmKZb3LK9Kc" title="Ownership percentage">50% of the Company after the transaction and a liquidation, dissolution or winding-up of the Company, the notes will be repaid in cash or its portion of any non-cash consideration. The conversion rate for any issuance of shares of common stock will be at the then fair value of a share of common stock, with the fair value being determined with reference to the public market price of a share of common stock, but not less than $<span id="xdx_90B_eus-gaap--SharePrice_iI_c20250409__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrNealGoldmanMsBenedettaCasamentoAndDrDidierDemesminMember_zL8RPbNItnW8" title="Market price">0.50. The notes are unsecured and have typical default terms. On April 20, 2026, the Company completed the Private Placement of <span id="xdx_907_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20260420__20260420__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zKtwxCn69aLl">7,962,963 units at a purchase price of $<span id="xdx_90B_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20260420__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zOqUCq73qSTg">0.27 per unit, generating gross proceeds of approximately $<span id="xdx_90D_eus-gaap--SaleOfStockConsiderationReceivedPerTransaction_pn4n6_c20260420__20260420__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zSzPDJ2y2Kc2">2.15 million, consisting of $1.80 million in cash and a reduction of $351,000 in outstanding principal of the Company’s Convertible Notes, the holders of which applied such principal amounts toward the purchase of units in the offering in lieu of cash. Each of Mr. Neal Goldman, Ms. Benedetta Casamento, and Dr. Didier Demesmin reduced their outstanding aggregate principal amount of Convertible Notes by $<span id="xdx_901_eus-gaap--ConvertibleNotesPayable_iI_c20260420__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrNealGoldmanMember_z2NpaSrnnRm4">219,000, $<span id="xdx_906_eus-gaap--ConvertibleNotesPayable_iI_c20260420__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsBenedettaCasamentoMember_zd2hvwKM6ct6">87,750, $<span id="xdx_902_eus-gaap--ConvertibleNotesPayable_iI_c20260420__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrDidierDemesminMember_zGe9VyyUDEPa">43,875 and received <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20260420__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrNealGoldmanMember_zxYP4ktoYJti">812,501 <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20260420__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsBenedettaCasamentoMember_zpK4QXTPw6v9">325,000 <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20260420__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrDidierDemesminMember_zNlcIv8BJwL5">162,500 shares and warrants respectively. BP4 S.r.l. / Innovest S.p.A. BP4 S.r.l. / Innovest S.p.A.\n\nBP4 S.r.l. (“BP4”) is a significant shareholder of the Company, beneficially owning approximately <span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateDuringPeriod_pid_dp_uPure_c20260101__20260331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovestSPAMember_zb1nYNtZwQEf" title="Interest rate">11.31% of the Company’s outstanding common stock, and is considered a related party. On January 15, 2026, the Company entered into an Amended and Restated Memorandum of Understanding (the “MOU”) with Innovest S.p.A., as the holder of certain consent and blockage rights with respect to BP4. <span id="xdx_901_eus-gaap--RelatedPartyTransactionDescriptionOfTransaction_c20260115__20260115__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovestSPAMember_zyAFqHobZCS6" title="Related party transaction description of transaction">Pursuant to the MOU, and subject to certain conditions, BP4 agreed to enter into a lock-up agreement pursuant to which it would not distribute or sell any of its shares of capital stock of the Company for twelve months following consummation of a $2.5 million offering by the Company. The lock-up provides for early release if the Company’s stock price exceeds specified thresholds for a defined period, permitting partial distributions of shares to BP4’s quotaholders. The Company paid BP4 $32,000 in respect of additional disbursements accumulated in connection with the transaction contemplated by the MOU, which payments are subject to an aggregate cap of $100,000. On March 31, 2026, the Company entered into an amendment to the MOU to, among other things, revise the definition of “Qualified Offering” and “Other Locked-Up Parties” in order to facilitate an offering by the Company.

249000

487000

801000

1100000

96000

112000

25000

39000

384000

289000

-100000

200000

100000

200000

P9Y6M

50000

2000000

P5Y

P10Y

2844028

3221786

6000

22300

25500

150000 67000 67000 67000 150000

89000

66000 912736

800000

0.0250

4000000 4000000

0.50

7962963

0.27

2150000

1800000

351000

219000

87750

43875

812501

325000

162500

0.1131

Pursuant to the MOU, and subject to certain conditions, BP4 agreed to enter into a lock-up agreement pursuant to which it would not distribute or sell any of its shares of capital stock of the Company for twelve months following consummation of a $2.5 million offering by the Company. The lock-up provides for early release if the Company’s stock price exceeds specified thresholds for a defined period, permitting partial distributions of shares to BP4’s quotaholders. The Company paid BP4 $32,000 in respect of additional disbursements accumulated in connection with the transaction contemplated by the MOU, which payments are subject to an aggregate cap of $100,000.

NOTE 12 — COMMITMENTS (1) Contract Manufacturing Agreement Milestone Scientific has informal arrangements with third-party manufacturers of the STA devices and epidural instruments pursuant to which they manufacture these products under specific purchase orders but without any long-term contract or minimum purchase commitment. The Company has a purchase commitment for the delivery of 1,900 STA instruments as of March 31, 2026. As of March 31, 2026 and December 31, 2025, the purchase order commitment was approximately $<span id="xdx_906_eus-gaap--PurchaseCommitmentRemainingMinimumAmountCommitted_iI_pn5n6_c20260331__us-gaap--PurchaseCommitmentExcludingLongtermCommitmentAxis__custom--PurchaseCommitmentForDevicesMember_zGtMIK4Y61Td">2.3 million, respectively, and approximately $1.4 million was paid and reported in advance on contracts in the unaudited condensed consolidated balance sheet. The advances in contracts represent funding for future epidural instruments and epidural replacement parts. As of March 31, 2026 and December 31, 2025, the company also has advances on an open purchase order for long lead items for a future purchase order for the manufacturing of Epidural instruments of approximately $<span id="xdx_901_eus-gaap--AdvancesOnInventoryPurchases_iI_c20260331__us-gaap--PurchaseCommitmentExcludingLongtermCommitmentAxis__custom--ContractsForFundingOfFutureEpiduralInstrumentsAndPartsMember_zUDYr7XjnpYd" title="Advances on inventory purchases"><span id="xdx_90E_eus-gaap--AdvancesOnInventoryPurchases_iI_c20251231__us-gaap--PurchaseCommitmentExcludingLongtermCommitmentAxis__custom--ContractsForFundingOfFutureEpiduralInstrumentsAndPartsMember_z0nVBjLxmpy" title="Advances on inventory purchases">34,000, respectively. (2) Operating Leases The Company identified and assessed the following significant assumptions in recognizing its right-of-use assets and corresponding lease liabilities: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">As the Company’s leases do not provide an implicit rate, the Company estimated the incremental borrowing rate in calculating the present value of the lease payments. The Company has utilized its incremental borrowing rate based on the long-term borrowing costs of comparable companies in the Medical Device industry.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Since the Company elected to account for each lease component and its associated non-lease components as a single combined lease component, all contract consideration was allocated to the combined lease component.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The expected lease terms include non-cancellable lease periods. Renewal option periods are not included in the determination of the lease terms as they were not reasonably certain to be exercised.</td></tr> </table> The components of lease expense were as follows: SCHEDULE OF COMPONENTS OF LEASE EXPENSE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49F_20260101__20260331_zrgeZ6ghfWuj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_499_20250101__20250331_zlb0TBbJswK3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three months ended</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40F_eus-gaap--OperatingLeasePayments_zrIIVvULfHig" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Cash paid for operating lease liabilities</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">31,882</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">31,882</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--FinanceLeaseInterestPaymentOnLiability_zzKqB3zl5sV4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Cash paid for finance lease liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,417</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,417</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Weighted Average Remaining Lease Term</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Finance leases (years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> 3.67 years</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> 4.75 years</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Operating leases (years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> 1.00 years</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> 2.00 years</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Weighted-average discount rate – operating leases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9.20</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9.20</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Weighted-average discount rate – finance leases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9.20</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9.20</td><td style="text-align: left">%</td></tr> </table>

1900

2300000

1400000

34000

The components of lease expense were as follows: SCHEDULE OF COMPONENTS OF LEASE EXPENSE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49F_20260101__20260331_zrgeZ6ghfWuj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_499_20250101__20250331_zlb0TBbJswK3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three months ended</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40F_eus-gaap--OperatingLeasePayments_zrIIVvULfHig" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Cash paid for operating lease liabilities</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">31,882</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">31,882</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--FinanceLeaseInterestPaymentOnLiability_zzKqB3zl5sV4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Cash paid for finance lease liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,417</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,417</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Weighted Average Remaining Lease Term</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Finance leases (years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> 3.67 years</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> 4.75 years</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Operating leases (years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> 1.00 years</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> 2.00 years</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Weighted-average discount rate – operating leases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9.20</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9.20</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Weighted-average discount rate – finance leases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9.20</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9.20</td><td style="text-align: left">%</td></tr> </table>

31882

3417

P3Y8M1D

P4Y9M

P1Y

P2Y

0.0920

NOTE 13 — SUBSEQUENT EVENT On April 20, 2026, the Company completed a private placement of <span id="xdx_902_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20260420__20260420__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z4wmYnOBf6Ob" title="Sale of stock number of shares issued in transaction">7,962,963 units at a purchase price of $<span id="xdx_900_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20260420__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zrt6TnlcckZ7" title="Sale of stock price per share">0.27 per unit, generating gross proceeds of approximately $<span id="xdx_907_eus-gaap--SaleOfStockConsiderationReceivedPerTransaction_pn4n6_c20260420__20260420__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zFKvE4s8oto" title="Sale of stock consideration received per transaction">2.15 million, consisting of $1.80 million in cash and a reduction of $351,000 in outstanding principal of the Company’s Convertible Notes, the holders of which applied such principal amounts toward the purchase of units in the offering in lieu of cash. Each unit consisted of one share of common stock and one warrant to purchase one share of common stock at an exercise price of $<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260420__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zftS2xINboph" title="Warrant exercise price">0.3375 per share, exercisable for a period of three years. If fully exercised, the warrants would provide up to approximately $<span id="xdx_907_eus-gaap--ProceedsFromWarrantExercises_pn4n6_c20260420__20260420__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zX18sxIIxZjd" title="Proceeds from warrant exercise">2.69 million in additional gross proceeds. The Company incurred approximately $<span id="xdx_90D_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_c20260420__20260420__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zLbvO09DcJ8h" title="Proceeds from issuance of private placement">332,000 in costs associated with the private placement, including legal expenses, which is recorded as deferred financing costs on the balance sheet as of March 31, 2026.

7962963

0.27

2150000

1800000

351000

0.3375

2690000

332000

true